POLYCYCLIC GUANINE DERIVATIVES

Abstract: Novel polycyclic guanine derivatives of formula (I) and (I'), wherein J is oxygen or sulfur, R<1> is hydrogen, alkyl or alkyl substituted with aryl or hydroxy; R<2> is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl or alkyl substituted with aryl, heteroaryl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino, or -(CH2)mTCOR<20> wherein m is an integer from 1 to 6, T is oxygen or -NH- and R<20> is hydrogen, aryl, heteroaryl, alkyl or alkyl substituted with aryl or heteroaryl; R<3> is hydrogen, halo, trifluoromethyl, alkoxy, alkylthio, alkyl, cycloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl or aminocarbonyl or alkyl substituted with aryl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino; R<a>, R<b>, R<c> and R<d> independently represent hydrogen, alkyl, cycloalkyl or aryl; or (R<a> and R<b>) or (R<c> and R<d>) or (R<b> and R<c>) can complete a saturated ring of 5- to 7- carbon atoms, or (R<a> and R<b>) taken together and (R<b> and R<c>) taken together, each complete a saturated ring of 5- to 7- carbon atoms, wherein each ring optionally can contain a sulfur or oxygen atom and whose carbon atoms may be optionally substituted with one or more of the following: alkenyl, alkynyl, hydroxy, carboxy, alkoxycarbonyl, alkyl or alkyl substituted with hydroxy, carboxy or alkoxycarbonyl; or such saturated ring can have two adjacent carbon atoms which are shared with an adjoining aryl ring; and n is zero or one. The compounds of formulas (I) and (I') are useful as antihypertensive, muscle relaxant and bronchodilating agents.

Description: POLYCYCLIC GUANINE DERIVATIVES BACKGROUND The present invention relates to polycyclic guanine derivatives useful for treating cardiovascular and pulmonary disorders, as well as to their pharmaceutical compositions and methods for using the same. SUMMARY OF THE INVENTION The present invention is directed to novel polycyclic guanine derivatives of the formula: wherein J is oxygen or sulfur, R 1 is hydrogen, alkyl or alkyl substituted with aryl or hydroxy; R2 is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl or alkyl substituted with aryl, heteroaryl, hydroxy, alkoxy, amino, monoalkyl amino or dialkylamino, or -(CH2)rnTCOR 20 wherein m is an integer from 1 to 6, T is oxygen or -NH- and R 20 is hydrogen, aryl, heteroaryl, alkyl or alkyl substituted with aryl or heteroaryl; R 3 is hydrogen, halo, trifluoromethyl, alkoxy, alkylthio, alkyl, cycloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl or aminocarbonyl or alkyl substituted with aryl, hydroxy, alkoxy, amino, monoalkylamino or dialkylamino; R a , R b , R c and R d independently represent hydrogen, alkyl, cycloalkyl or aryl; or (R a and R b ) or (R c and R d ) or (R b and R c ) can complete a saturated ring of 5- to 7- carbon atoms, or (R a and R b ) taken together and (R b and R c ) taken together, each complete a saturated ring of 5- to 7-carbon atoms, wherein each ring optionally can contain a sulfur or oxygen atom and whose carbon atoms may be optionally substituted with one or more or the following: alkenyl, alkynyl, hydroxy, carboxy, alkoxycarbonyl, alkyl or alkyl substituted with hydroxy, carboxy or alkoxycarbonyl; or such saturated ring can have two adjacent carbon atoms which are shared with an adjoining aryl ring; and n is zero or one. Preferred compounds are those of formula (I). Preferably, J is O. Also preferred is that R 1 is alkyl, more preferably methyl. For R 2 , preferred substituents include hydrogen, benzyl, 4-chlorobenzyl, cyclohexylmethyl and trimethylacetoxymethyl. For R 3 , preferred substituents include hydrogen and alkyl such as methyl or ethyl. Preferably n is zero. Also preferred is that (R a and R b ) form a saturated 5 membered ring, that (R b and R c ) form a saturated 5, 6 or 7 membered ring or (R a and R b ) and (R b and R c ) each can complete a saturated ring and each ring contains 5 or 6 carbon atoms . When (R b and R c ) form a saturated 5, 6 or 7 membered ring, generally the preferred stereochemistry is (R) at the carbon atom bearing R b and the preferred stereochemistry is (S) at the carbon atom bearing R c . The compounds of formulas (I) and (I') are useful as antihypertensive, bronchodilating and blood platelet inhibiting agents. Compounds (I) and (I') are also useful in inhibiting phosphodiesterase enzymes. The inhibition of vascular phosphodiesterase is believed to induce antihypertensive activity. Compounds (I) and (I') can also serve as smooth muscle relaxants and are therefore useful in the treatment of bronchoconstriction. Such compounds also can inhibit platelet function and are useful in treating conditions benefitting from inhibiting platelet function. The present invention is also directed toward a pharmaceutical composition containing at least one of compounds (I) and (I * ) in an amount effective to inhibit phosphodiesterase or relax smooth muscle. The present invention is also directed toward a pharmaceutical composition containing an anti-hypertensive, a bronchodilating or a platelet inhibiting effective amount of the compounds (I) and (I'). The present invention is also directed toward a method for treating hypertension, bronchoconstriction or diseases benefitting from platelet inhibition in a mammal comprising administering to a mammal in need of such treatment an amount of at least one of compounds (I) and (!') effective to treat any of the above diseases. The present invention is also directed toward a method for maintaining guanosine 3':5'-cyclic monophosphate (cGMP) levels in a mammal by administering an amount of compounds (I) and (I') effective to maintain or increase cGMP levels. DETAILED DESCRIPTION OF THE INVENTION alkyl - represents a straight chain saturated hydrocarbon moiety having from 1 to 10, preferably from 1 to 6 carbon atoms or a branched hydrocarbon moiety of 3 to 10 carbon atoms, preferably from 3 to 6, such as for example methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl, decyl and the like; alkoxy - represents an alkyl moiety as defined above covalently bonded to an oxygen atom, as for example, methoxy, ethoxy, propoxy, pentyloxy, hexyloxy, decyloxy and the like; alkenyl - represents a straight chain hydrocarbon chain hydrocarbon moiety of two to 10 carbon atoms or a branched hydrocarbon moiety of three to 10 carbon atoms having at least one carbon-to-carbon double bond such as ethenyl , 1-propenyl, 1-butenyl, 2-butenyl, isobutenyl, 1-pentenyl, 2-methyl-1-butenyl, 1-hexenyl and the like; alkynyl - represents a straight chain hydrocarbon moiety of two to 10 carbon atoms or a or branched hydrocarbon chain of four to 10 carbon atoms having at least one carbon to carbon triple bond such as for example ethynyl, 1-propynyl, 1-butynyl, 1-pentynyl, 2-pentynyl, 1- hexynyl, 2-hexynyl, 3-hexynyl and the like; alkylthio - represents an alkyl moiety as defined above bonded to a sulfur atom; aryl - represents a carbocyclic moiety containing at least one benzenoid-type ring, with the aryl moiety having from 6 to 14 carbon atoms.with all available substitutable carbon atoms of the aryl moiety being intended as possible points of attachment, for example phenyl, naphthyl, indenyl, indanyl and the like, and wherein said carbocyclic moiety can be optionally substituted with one to three moieties independently selected from the following: halo, alkyl, trifluoromethyl, phenyl, hydroxy, alkoxy, phenoxy, amino, monoalkylamino or dialkylamino; cycloalkyl - represents a saturated carbocyclic ring containing from 3 to 7 carbon atoms, such as for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like; halo - represents fluoro, chloro, bromo or iodo; heteroaryl - represents a cyclic group having at least one O, S and/or N interrupting a carbocyclic ring structure and having a sufficient number of delocalized pi electrons to provide aromatic character, with the aromatic heterocyclic group having from 2 to 14, preferably from 2 to 6 carbon atoms, for example 2-, 3- or 4-pyridyl, 2- or 3-furyl, 2- or 3-thienyl, 2-, 4- or 5-thiazolyl, 1 , 2-, 4- or 5-imidazolyl, 2-, 4- or 5-pyrimidinyl, 2-pyrazinyl, 3- or 4-pyridazinyl, 3-, 5- or 6-[1 ,2,4- triazinyl], 3- or 5-[1 ,2,4-thiadazolyl], 2-, 3-, 4-, 5-, 6- or 7-benzofuranyl, 1-, 2-, 3-, 4-, 5-, 6- or 7-indolyl, 1-, 3-, 4- or 5-pyrazolyl, 2-, 4- or 5- oxazolyl and the like; aminosulfonyl- a sulfonyl moiety bonded to an amino or alkylamino moiety of one to six carbon atoms, e.g. -SO2NH2, -S0 2 NHCH 3l -S0 2 N(CH 3 ) 2 and the like.; monoalkylamino - an amino moiety in which one of the hydrogens has been substituted with an alkyl moiety as defined hereinbefore; dialkylamino - an amino moiety in which each of the hydrogens has been substituted independently with an alkyl moiety; Certain compounds of the invention e.g., those with a basic nitrogen containing moiety, can also form pharmaceutically acceptable salts with organic and inorganic acids. Examples of suitable acids for such salt formation are hydrochloric, sulfuric, phosphoric, acetic, citric, oxalic, malonic, salicylic, malic, fumaric, succinic, ascorbic, maleic, methanesulfonic and other mineral and carboxylic acids well known to those skilled in the art. The salts are prepared by contacting the free base form with a sufficient amount of the desired acid to produce a salt in the conventional manner. Certain compounds of the invention will be acidic in nature, e.g., those compounds which possess a carboxy or phenolic hydroxyl group. These compounds may form pharmaceutically acceptable salts. Examples of such salts are the sodium, potassium, calcium, aluminum, gold and silver salts. Also contemplated are salts formed with pharmaceutically acceptable amines such as ammonia, alkylamines, hydroxyalkylamines, N-methylglucamine and the like. The compounds of the present invention can be prepared by several preparative routes as described hereinafter. Variations of these routes can be employed, as well as other routes known to those skilled in the art such as those described in the various references cited throughout the specification, whose preparative teachings are incoporated herein by reference. ln Route 1 , the compounds of formula (IV) can be prepared by contacting compound (II) with a nitrosating agent such as nitrous acid, as described in Arnold Weissberger (ed.), The Chemistry of Heterocyclic Compounds, A Series of Monographs, The Pyrimidines, Interscience Publishers, John Wiley & Sons, New York (1962), whose preparative teachings are incorporated herein by reference. The compounds of formula (VI) can be prepared by contacting compound (IV) with a reducing agent such as hydrogen with a catalyst, a metal with an acid, or a sulfur containing reducing agent such as sodium dithionite, as described in Weissberger, supra. The compounds of formula (VIII) can be prepared by reductive alkylation of compounds (VI) entailing contacting compound (VI) with a carbonyl compound and reducing the intermediate thus obtained by catalytic hydrogenation as described hereinbefore or by reduction with a hydride reducing agent such as sodium cyanoborohydride, as described in Mary Fieser and Louis Fieser, Reagents for Organic Synthesis, Vol. 1-13, John Wiley & Sons, New York (1979-88), whose preparative teachings are incorporated herein by reference. The compounds of formula (XIV) can be prepared by cyclizing the adduct prepared from compound (VIII) with a carboxylic acid derivative such as an orthoester of the formula R3C(OCH3)3 as taught in Weissberger, The Chemistry of Heterocyclic Compounds, A Series of Monographs, The Fused Pyrimidines, Vol. 2, Purines, Interscience Publishers, John Wiley & Sons, New York (1967). The compounds of formula (XVI) wherein X is CI or Br can be prepared by converting compounds (XIV) to their halide form with a halide forming reagent such as phosphorus oxychloride (POCI3) as taught in Weissberger, The Fused Pyrimidines, supra. The compounds of formula (XIX) can be prepared by amination of compounds (XVI) with aminoalcohol (XVIII) optionally in the presence of a suitable acid acceptor such as triethylamine, according to known or analogous procedures such as taught in Weissberger, The Fused Pyrimidines, supra. A particularly useful method employs excess diisopropylethylamine in a solvent such as N-methylpyrrolidinone at elevated temperatures of 100 to 150°C. The desired compounds of formula (I) can be prepared by ring closure of compound (XIX) with a suitable dehydrating agent such as thionyl chloride or triphenylphosphine dibromide according to known or analogous procedures as taught in Fieser and Fieser, supra. The compounds of formula (I) and (I') wherein R 1 or R 2 is benzyl or substituted benzyl can be converted to the corresponding intermediate compounds (I) and (I') wherein R 1 or R 2 is hydrogen by hydrogenolysis, as for example, with hydrogen and palladium catalyst. The corresponding intermediate compounds (I) and (I') wherein R 1 or R 2 is hydrogen can then be converted to compounds (I) and (I') wherein R 1 or R 2 represents the non-hydrogen substituents for R 1 and R 2 , with an alkylating agent R 1 Y or R Y, wherein Y is a leaving group, e.g., halo or sulfonate such as mesylate or triflate, in the presence of a suitable base. f R 1 Y 1 R 1 Y 1 Routes 2 & 3 -Continued In Routes 2 and 3, compound (XXI) can be prepared by contacting the 2,6-dichloropurine compound (XX) with a benzylic alcohol of the formula R 5 OH, wherein R 5 represents benzyl or substituted benzyl, in the presence of a suitable base such as sodium hydride (NaH) in a solvent such as DMF or THF. Compound (XXI) is contacted with a compound of the formula R 2 Y wherein R 2 and Y are as defined hereinbefore in the presence of a base such as potassium carbonate (K2CO3) and a solvent such as dimethylformamide (DMF) to give a mixture containing monochlorinated purines (XXII) and (XXX). These compounds are then separated by conventional procedures, such as chromatography or crystallization. In Route 2, compound (XXII) can be contacted with an acid such as HX wherein X is chloro or bromo in an organic acid such as acetic acid to give the compound (XXIII). Compound (XXIII) can then be contacted with a compound of formula R 1 Y 1 wherein R 1 is defined hereinbefore and Y 1 is a leaving group representing any of the values for Y, in the presence of a base such as lithium hydroxide in dimethylformamide, as described in D. Ranganathan and F. Farooqui, Tet. Lett. 25, 5701 (1984) to give compound (XVI). Compound (XVI) can be converted to the desired compound (I) as described in Route 1. Similarly, in Route 3, desired compounds (I') can be prepared according to the procedures as described in Routes 1 and 2. Route 4 ile In Route 4, the compounds of formula (I) or (I') wherein R 3 is alkyl, halo, alkylthio, carboxy or alkoxycarbonyl, can be prepared by, in step 1 , contacting compound (I) or (I') wherein R 3 is hydrogen, with a base such as lithium diisopropylamide (LDA) in a suitable solvent such as THF. In step 2, the adduct from step 1 is treated with a corresponding electrophile giving R 3 , such as halogen, e.g. Br2 giving R 3 =Br, a disulfide, e.g. CH3SSCH3 giving R 3 =CH3S, carbon dioxide (CO2) giving R 3 =COOH, methyl iodide (CH 3 I) giving R 3 =CH 3 , and the like. See H. Hayakawa, K. Haraguchi, H. Tanaka and T. Miyasaka, Chem. Pharm. Bull., 35(1), pp. 72-79 (1987) for analogous procedures. The compounds of formula (I) wherein R 3 is amino, monoalkylamino, dialkylamino, alkylthio or alkoxy can be prepared by contacting a compound of formula (I) wherein R 3 is halogen with an amine, alkyl mercaptide or alkoxide to form the corresponding amino, alkylthio or alkoxy compound (I) as taught in Weissberger, The Fused Pyrimidines, supra. grating I saturating Agent Agent In Route 5, the sulfur containing compounds (I), and (I') wherein J=S, can be prepared by contacting the oxygen containing compounds (I) and (I') wherein J=0, with a sulfurating agent such as phosphorus pentasulfide (P2S5), or Lawesson's reagent, as taught in J. March, Advanced Organic Chemistry, Reactions, Mechanisms and Structure, 3rd Edition, John Wiley & Sons, New York, (1985), pp. 793- 795, whose preparative teachings are incorporated herein by reference. Scheme 1 (LV) (XVIIIa) Aminoalcohols (XVIII) are known or may be prepared by known methods, such as taught in Rodd's Chemistry of Carbon Compounds, 2nd Edition, Vol. 1 , Part D., pp 34-37, whose preparative teachings are incoporated herein by reference. Compounds (XVIIIa) represent the case where (R a and R b ) and (R b and R c ) each complete a saturated ring, R b is CH, and n is 0. These may be prepared according to Scheme 1 , where p is 2 or 3, and R a , R c , and R d are as defined hereinbefore. Compound (Llll) can be prepared by treating compound (LI) with an organometallic reagent (Lll), ie. grignard reagent or a zinc copper reagent as described in E.J. Corey et al., Journal of American Chemical Society, 1978 page 6294 or P. Knochel et al., Journal of Organic Chemistry, 1989, pg. 5200, whose preparative teachings are incorporated herein by reference. Compound (LIV) can be prepared by treating compound (I— III) with a protic acid in alcohol , e.g. toluenesulfonic acid or hydrochloric acid in methanol, at refluxing temperatures, followed by treatment with an aqueous solution of a protic acid in a solvent such as hydrochloric acid in THF. Subsequent treatment with a base, e.g. potassium carbonate in an alcoholic solvent such as methanol, gives compound (LIV). Compound (XVIIIa) can be prepared by treating compound (LIV) with a reducing agent, e.g. by hydrogenation with Raney nickel or reduction with sodium borohydride in an alcohol solvent, e.g methanol. Alternatively, when R d is H, compound (XVIIIa) can be prepared by treating compound (LIV) with an oxidizing agent such as pyridinium chlorochromate (PCC) to give ketone (LV), followed by reduction with a reducing agent such as borodydride in an alcoholic solvent, followed by hydrogenation with a suitable catalyst, eg. Raney nickel, to give the desired compound (XVIIIa). The following examples are presented to illustrate typical compounds of the present invention, but the scope of the invention is not to be considered limited to such examples. Example 1 : cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(phenylmethyl)- cyclopent[4,5]imidazo[2,1-b]purin-4-one Add 3.2 g SOCI (27 mmol) to a solution of 2-(trans-2- hydroxycyclopentylamino)-1-methyl-7-(phenylmethyl)purin-6-one (3.0g=8.8mmol) in 150 ml CH2CI2. Stir the solution overnight, wash with cold 2 N NaOH, dry, and solvent strip. Chromatograph the residue on silica (98:2 CH 2 CI 2 /CH 3 OH) to give the title compound as a foamed solid. FAB MS: M+1=322. Example 2: 7,8-Dihydro-5-methyl-3-(phenylmethyl)-3H- imidazo[2,1-b]purin-4(5 : M+=281. By using 2-(2-hydroxyethylamino)-1 -methyl-7-(phenylmethyl)purin-6- one in accordance with Example 1 , the title compound is obtained. Example 3: cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-3- (phenylmethyl)-3H-benzimidazo[2,1-b] purin-4(5H)-one: white foam, El MS: M+=335 By using 2-(trans-2-hydroxycyclohexylamino)-1-methyl-7- (phenylmethyI)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 4: 5,7,8,9-Tetrahydro-5-methyl-3- (phenylmethyl)pyrimido[2,1 -b]purin-4(3H)-one, hydrochloride: white solid, FAB MS: M-HCI=295 By using 2-(3-hydroxypropylamino)-1 -methyl-7-(phenylmethyl)purin-6- one in accordance with Example 1 , the title compound is obtained. Example 5: 7,8-Dihydro-8-phenyl-5-methyl-3-(phenylmethyl)- By using 2-(2-hydroxy-2-phenylethylamino)-1-methyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 6: S'J'-Dihydro-δ'-methyl-S'- (phenylmethyl)spiro[cyclohexane-1,8'-(8H)-imidazo[2,1-b]purin]-4'(3Η)- one: white solid, CI MS: M+1=350. By using 2-(1-(hydroxycyclohexy " l) ~ mOethylamino)-1-methyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 7: cis-5,6a,11 ,11 a-Tetrahydro-5-methyl-3- (phenylmethyl)indeno[1 '^'tf.δjimidazo^.l -b]purin-4(3H)-one: foamed solid, CI MS: M+1 =374. By using 2-(2-hydroxy-1 -indanylamino)-1 -methyl-7-(phenylmethyl)purin- 6-one in accordance with Example 1 , the title compound is obtained. By use of the appropriate amino-alcohol in accordance with Example 1 , the following compounds are obtained: 7A8 S'J'-Dihydro- .δ' dimethyl-3'- (phenylmethy spirolcyclohexane-I δ'hD-infiidazo^.l-bJpurinJ^^S'Jl)- one: off-white solid, El MS: M+=363. 7A9 7,8-Dihydro-2,5,7,7,8(R,S)-pentamethyl-3tL- imidazo[2,1-b]purin-4(5IH)-one: white solid, El MS: M+=247. Example 8: cis-5,6a,7,11 b-Tetrahydro-5-methyl-3- (phenylmethyl)indeno[2\1\:4,5]imidazo[2,1-b]purin-4(3H)-one: white solid, CI MS: M+1 =370. By using 2-(1-hydroxy-2-indanylamino)-1-methyl-7-(phenylmethyl)purin- 6-one in accordance with Example 1 , the title compound is obtained. Example 9: cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethyl-3- (phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4-(3H)-one: off-white solid, CI MS: M+1 =336. By using 2-(trans-2-hydroxycyclopentylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. By use of the appropriate amino-alcohol in accordance with Example 1 , the following compounds are obtained: 9A3 5'-methyl-3'-(phenylmethyl)-spiro[cyclopentane- \ ,T(βΗ)-{-Η Hmidazo^.l-bjpurinj-^δ'H J-one: off-white solid, CI MS: M+1=336. 9A4. 7,8-Dihydro-2,5,7,7-tetramethyl-3-(phenylmethyI)-3j±- imidazo[2,1-b]purin-4(5'H)-one: white foamed solid, CI MS: M+1=324. 9A5 7,8-Dihydro-7(R)-phenyl-2,5-dimethyl-3- (phenylmethyl)-3H.-i idazo[2,1-b]purin-4(5Jl)-one: off-white solid, CI 9A6 7,8-Dihydro-2,5-dimethyl-3,7(R)-bis(phenylmethyl)- 3M-imidazo[2,1-b]purin-4(5M)-one: tan solid, El MS: M+=385. [α] D 23 5 = +11.6°. 9A7 (+)-7,8-Dihydro-2,5-dimethyl-7-ethyl-3- (phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one: tan solid, CI MS: M+1=324. 9A8 6a(S)-7,8,9,10,10a(R)-hexhydro-2,5-dimethyl-3- (phenylmethyl)-3H-ben?Imidazo[2,1-b]purin-4(5tl)-one: tan foam, CI 9A9 6a(R)-7,8,9,10,10a(S)-hexahydro-2,5-dimethyl-3- (phenylmethyl)-3M-benzimidazo[2,1 -b]purin-4(5Ji)-one: off-white foamed solid, CI MS: M+1 =350, [α] D 6= +83.0°. 9A10 7,8-Dihydro-2,5-dimethyl-7(R)-isopropyl-3- (phenylmethyl)-3 l-imidazo[2,1-b]purin-4(5ii)-one: tan solid, CI MS: 9A11 7,8-Dihydro-2,5,7(R)-trimethyl-3-(phenylmethyl)-3Ji- imidazo[2,1-b]purin-4(5H)-one: white solid, CI MS: M+1=310, [α] D 26 = 9A12 cis-7.7a.8.9.10,10a-Hexahydro-2,5-dimethyl-3- (phenylmethyl)-3ii-cyclopenta[5,6]pyrimido[2,1-b]purin-4(5H)-one: tan foamed solid, CI MS: M+1 =350. 9A13 7,8-Dihydro-2,5-dimethyl-7(S)-(1 -methyipropyl)-3- (phenylmethyl)-3H-imidazo[2,1-b]purin-4(5H)-one: crystalline solid, FAB 9A14 7,8-Dihydro-2,5-dimethyl-7(R)-(2-methylpropyl)-3- (phenylmethyl)-3Jl-imidazo[2,1-b]purin-4(5il)-one: clear gum, CI MS: 9A15 7,8-Dihydro-2,5-dimethyl-7(R,S)-(methoxycarbonyl)- 3-(phenylmethyl)-3il-imidazo[2,1-b]purin-4(5iH)-one: tan foam, FAB MS: M+1=354. 9A16 7,8-Dihydro-2,5-dimethyl-7(R,S)-(1 -propyl)-3- (phenylmethyl)-3il-imidazo[2,1-b]purin-4(5H)-one: tan solid, CI MS: 9A17 7,8-Dihydro-2,5-dimethyl-7(S)-(1 -methylethyl)-3- (phenylmethyl)-311- imidazo[2,1-b]purin-4(5tl)-one: white foamed solid, 9A18 7,8-Dihydro-2,5,7,7,8(R,S)-pentamethyl-3- (phenylmethyl)-3JH-imidazo[2,1-b]purin-4(5Jl)-one: off-white solid, El MS: M+=337. 9A19: 5,7,8,9-Tetrahydro-2,5,7,9(R,S)-pentamethyl-3- (phenylmethyl)-pyrimido[2,1-b]purin-4(3JH)-one: white solid, El MS: M+=351. Example 10: 5,6a( : ?),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3- (phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one: white solid, r i 26 CI MS: M+1=336, MD =+122.4°. By using 2-(2(fl)-hydroxy-1 ( ?)-cyclopentylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 11 : 5,6a(S),7,8,9,9a(f?)-Heκahydro-2,5-dimethyl-3- (phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one: white solid, r - 26 Cl MS: M+1=336, l α =-122.4°. By using 2-(2(S)-hydroxy-1 (S)-cyclopentylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 12: cis-6a,7,8,9,10,10a-Hexahydro-2,5-dimethyl-3- (phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one: white solid, CI By using 2-(trans-2-hydroxycyclohexylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 13: 5 * ,7 , -Dihydro-2 , ,5 , -dimethyl-3'- (phenylmethyl)spiro[cyclohexane-1 ,8'-(8H)-imidazo[2,1 -b]purin]-4'(3'H)- one: tan foamed solid, CI MS: M+1=364. By using 2-(1-(hydroxycyclohexyl)methylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 14: cis-5,6a,7,8,9,9a-Hexahydro-2,5-dimethyl-3- (phenylmethyl)cyclohept[6,7]imidazo[2,1-b]purin-4(3H)-one: pale yellow foam, FAB MS: M+1 =364. By using 2-(trans-2-hydroxycycloheptylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 15: cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-ethyl-3- (phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one: tan solid, El By using 2-(trans-2-hydroxycyclopentylamino)-8-ethyl-1 -methyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 16: cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-2-ethyl-3- (phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5H)-one: pale yellow solid, CI MS: M+1=364. By using 2-(trans-2-hydroxycyclohexylamino)-8-ethyl-1-methyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. By using the appropriate amino-alcohol in accordance with Example 1 , the following compounds are obtained: 16A1 cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2- ethyl-3-(phenylmethyl)-cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one: tan solid, El MS: M+=349. Example 17: cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-2-phenyl-3- (phenylmethyl)cyclopent[4,5]imidazo[2,1 -b]purin-4(3H)-one: white solid, FAB MS: M+1=398. By using 2-(trans-2-hydroxycyclopentylamino)-1 -methyl-8-phenyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Exam p le 17a cis-6a,7,8,9,10,10a-Hexahydro-5-methyl-2-phenyl- 3-(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(5 -/)-one FAB MS: M+1=412. By using 2-(trans-2-hydroxycyclohexylamino)-1 -methyl-8-phenyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound, a white foam, is obtained. Example 18: cis-5,6a,7,8,9,9a-Hexahydro-o-methylcyclopenta[4 > 5]- imidazo[2,1 -b]purin-4(3H)-one. Hydrogenate cis-5,6a,7,8,9,9a-hexahydro-5-methyl-3- (phenylmethyl)cyclopenta[4,5]imidazo[2,1-b]purin-4-one (0.3g=0.93mmol) at room temperature/60psi in EtOH (125ml) containing 0.4g Pearlman catalyst. Filter catalyst, remove solvent, and recrystallize to give the title compound as a white solid. FAB MS: M+1=232. Example 19: is-5,6a,7,8,9,9a-Hexa ydro-2,5- dimethylcyclopenta[4,5]imidazo[2,1 -b]-purin-4(3H)-one, hydrochloride: white solid, El MS: M-HCI=245. By using cis-5,6a,7,8,9,9a-hexahydro-2,5-dimethyl-3-(phenylmethyl)- cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one in accordance with Example 18, the title compound is obtained. Example 19a. cis-5.6a(R).7.8.9.9a(S -Hexahydro-2.5-di-methyl- cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one: white solid, CI MS: By hydrogenating 5,6a(fl),7,8,9,9a(S)-hexahydro-2,5-dimethyl-3- (phenylmethyl)cyclopent[4,5]imidazo[2,1 -b]purin-4(3H)-one from Example 10 in accordance with Example 18, the title compound is obtained. By hydrogenating the corresponding benzyl derivative, the following compounds are obtained in accordance with Example 18. 19b 2'-Methyl-3 , -spiro{cyclopentane-1 ,7( ~ '&H3'ti}- imidazo [2,1-b]purin}-4 * (5'H)-one: white solid, CI MS: M+1=260. 19c 7,8-Dihydro-2,5-dimethyl-7(R)-(1 -methylethyl)-3H- imidazo[2,1-b]purin-4(5H)-one: off-white solid, CI MS: M+1=248. 19d 7,8-Dihydro-2,5,7,7-tetramethyl-3H-imidazo[2,1 b]purin-4(5JH)-one: white solid, CI MS: M+1=234. 19e 7,8-Dihydro-2,5-dimethyl-7(S)-(1 -methylethyl)-3H- imidazo[2,1-b]purin-4(5M)-one: pale yellow solid, CI MS: M+1=248. 19f 6a(R),7,8,9,10,10a(S)-Hexahydro-2,5-dimethyl-3H- benzimidazo[2,1-b]purin-4(5H)-one: off-white solid, CI MS: M+1=260. [α] D 22 = +116.3°. 19g δ\7'-Dihydro-2',δ'-dimethylspiro{cyclohexane- 1 ,7'(8Η)-imidazo[2,1-b]purin}-4'(3Η)-one: white solid, CI MS: M+1=274. Example 20: cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3- (phenylmethyl)cyclopenta[4,δ]imidazo[2,1-b]purin-4(3H)-thione. Treat cis-δ,6a,7,8,9,9a-hexahydro-δ-methyl-3-(phenylmethyl) cyclopenta[4,δ]imidazo[2,1 -b]purin-4 3H one (0.16g=0.δmmol)with Lawesson's reagent (0.2g=0.δmmol) in xylene overnight. Remove solvent and chromatograph on silica, eluting with 98:2 CH2Cl2/MeOH to give the title compound as a yellow foam. FAB MS: M+1 =338. Example 20a: δ,6a(fl),7,8,9,9a(S)-hexahydro-2,δ-dimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-thione FAB MS: M+=3δ2. By treating δ,6a(fl),7,8,9,9a(S)-hexahydro-2,δ-dimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1 -b]purin-4(3H)-one in δ accordance with Example 20, the title compound is obtained. Example 21 : cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3-(4-chlorophenyl- methyl)cyclopenta[4,δ]imid 0 Add a solution of cis-δ,6a,7,8,9,9a-hexahydro-5-methylcyclopenta[4,5]- imidazo[2,1-b]purin-4-one (O.δg=2.2mmol) in DMF drop-wise to a slurry of 60% NaH (0.1g=2.4mmol) in DMF at 30°C. When gas evolution ceases, add 4-chlorobenzyl chloride (O.δg=2.4mmol) in 2 ml DMF. Heat at δO°C. two hours. Remove DMF and parthisn between EtOAc and δ water. Dry, solvent strip, and recrystallize from CH3CN to give the title compound, a white solid. CI MS: M+=3δ6. Example 22: cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3- (cyclohexylmethyl)cyclopent[4,δ]imidazo[2,1-b3purin-4(3H)-one: off- 0 white foam, FAB MS: M+1=328. By using bromomethylcyclohexane in accordance with Example 21 , the title compound is obtained. δ Example 23: cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3-(2- naphthylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one: white foamed solid, FAB MS: M+1=372. By using 2-(bromomethyl)naphthalene in accordance with Example 21 , 0 the title compound is obtained. By use of the appropriate alkyl halide in accordance with Examples 21-23, the following compounds are obtained: 23A1 δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3-(4- bromophenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one: δ yellow crystals, El MS: 3δ - 23A2 δ,6a(R)-7,8,9,9a(S)-Hexahydro-2,δ-dimethyl- 3-(4- methoxyphenylmethyl)-cyclopent[4,δ]imidazo[2,1-b]purin-4(3Jl)-one: yellow solid, CI MS: M+1= Exam p le 24: cis-δ,6a,7,8,9,9a-Hexahydro-2,3,δ- trimethylcyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one: tan solid, FAB MS: M+1=260. By using cis-5,6a,7,8,9,9a-hexahydro-2,5- dimethylcyclopent[4,δ]imidazo[2,1 -b]purin-4 H one hydrochloride, and methyl iodide instead of 4-chlorobenzyl chloride in accordance with Example 21 , the title compound is obtained. Example 25: cis-δ,6a,7,8,9,9a-Hexahydro-2-(hydroxymethyl)-δ- methyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3 ^)one cis-5,6a,7,8,9,9a-Hexahydro-5-methyl-3-(phenylmethyl)- cyclopent .δjimidazo^.l-bjpurin^βHJ-one ( 0.3gm, 0.93mmol) in THF (4ml) is added to a solution of LDA (prepared from diisopropylamine (0.34ml) in THF (2ml) and 2.δ M n-butyllithium (1.0 ml), at -78°C. After 1 δ hr at -78°C, formaldehyde is bubbled into the reaction mixture for 10 min.. The mixture is stirred at -78°C for 30 min., then warmed to room temperature over 30 min. and acetic acid, brine, and CH2CI2 are added. The CH2CI2 layer is concentrated in vacuo and purified by flash chromatography using δ% MeOH in CH2CI2 to give the title compound, 0 a solid, mp 228-229°C. Example 26: cis-δ,6a,7,8,9,9a-Hexahydro-2-methylthio-δ-methyl- 3-(phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)one CI MS: M+1=368. δ By using LDA and 2.δ eq. CH3SSCH3 as the electrophile in accordance with Example 2δ, the title compound is obtained. 0 Example 27: cis-3,4,δ,6a,7,8,9,9a-Octahydro-δ-methyl-4-oxo-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-2-carboxylic acid, sodium salt, dihydrate FAB MS:M+1=324. By using LDA and excess carbon dioxide as the electrophile in accordance with Example 25, the title compound is obtained. Example 28: cis-3,4,δ,6a,7,8,9,9a-Octahydro-δ-methyl-4-oxo-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1 -b]purin-2-carboxylic acid, methyl ester, mp 18δ-186°C. The title compound of Example 27 is treated with ethereal CH2N2 to obtain the title compound. Exam p le 29: cis-δ,6a,7,8,9,9a-Hexahydro-2-bromo-δ-methyl-3- (phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)one FAB MS: M+1 =402, 400. By using 2.5 equivalents (eq) LDA and 2.5 bromine as the electrophile in accordance with Example 25, the title compound is obtained. Example 29a: cis-5,6a..7 :,9,9a-Hexahydro-2- (methylaminosulfonyl)-δ-metnyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)one By using LDA, sulfur chloride and aqueous methylamine in accordance with Example 2δ, the title compound is obtained, a solid. El MS: M=414. Example 30: cis-1 -Cyclopentyl-δ,6a,7,8,9,9a-hexahydro-δ- methylcyciopent[4,δ]imidazo[2,1 -b]purin-4(1 H)one A mixture of 2-bromo-1-methyl-9-cyclopentylpurin-6-one and 2-chloro-1- methyl-9-cyclopentylpurin-6-one (1.4 g) is mixed with (±) trans-2-aminocyclopentanol (1.2g, 11 mmol) and triethylamine (1.2ml) in CH3CN (20ml) and heated to reflux for 12 hr. The resultant mixture is cooled, concentrated in vacuo, and partitioned between EtOAc/THF 1 :1 and brine. The organic layers are concentrated in vacuo and the residue is purified by flash chromatography using 6% EtOH in CH2CI2 to give 2-(trans-2-hydroxycyclopentylamino)-1-methyl-9- cyclopentylpurin-6-one, a solid (1.4 gm, MS FAB: M+H=318 ). The 2- (trans-2-hydroxy cyclopentylamino)-1-methyl-9-cyclopentylpurin-6- one(1.3g, 4.1 mm), triphenylphosphine dibromide (prepared from triphenylphosphine (1.2 g) and bromine (0.2ml))in DMF (20 ml) is stirred at room temperature for 18 hr and heated to 70°C for 12hr. Dilute NaOH is added to the cooled reaction mixture to adjust the pH to 10, and the resultant solution is extracted with EtOAc/ THF 1 :1. The organic layer is concentrated in vacuo and purified by flash chromatography using 1δ% EtOH in CH2CI2 and recrystallized from CH2CI2/ hexane, to give the title compound, a solid, mp 194-19δ°C. δ Example 31 : cis-δ,6a,7,8,9,9a-Hexahydro-3,δ-bis (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one 0 Cyclize 2-(trans-2-hydroxycyclopentylamino)-1 ,7- bis(phenylmelhyl)purin-6-one in accordance with Example 1 to give the title compound, an off-white foamed solid CI MS: M+1=398. Example 32: cis-6a,7,8,9,10,10a-Hexahydro-3,δ- δ bis(phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(δH)one Cyclize 2-(trans-2-hydroxycyc Vlohexylamino)-1 ,7-bis(phenylmethyl)purin- 6-one in accordance with Example 1 to give the title compound, a tan foam, CI MS: M + 1 = 412. Example 33: cis-3-Cyclopentyl-δ,6a,7,8,9,9a-hexahydro-δ- methylcyclopent[4,δ]imidazo[2,1-b]purin-4(3H)one A mixture of 2-bromo-1-methyl-7-cyclopentylpurin-6-one and 2-chloro-1- methyl-7-cyclopentylpurin-6-one (11.4 g), (±) trans-2- aminocyclopentanol (1.2g, 11 mmol), and triethylamine (1.2ml) in δ CH3CN (20ml) is heated to reflux for 12 hr. The resultant mixture is cooled, concentrated in vacuo, and partitioned between EtOAcTHF 1 :1 and brine.The organic layers are concentrated in vacuo and the residue is purified by flash chromatography using 6% EtOH in CH2CI2 to give 2-(trans-2-hydroxycyclopentylamino)-1-methyl-7-cyclopentylpurin-6- 0 one, a colorless solid (1.4 gm, MS FAB: M+H=318). A mixture of 2- (trans-2-hydroxycyclopentylamino)-1-methyl-7-cyclopentylpurin-6-one (1.3gm, 4.1mm) and triphenylphosphine dibromide (prepared from triphenylphosphine (1.2g) and 0.2 ml bromine) in DMF (20ml) is stirred at room temperature for 18hr and heated to 70°C for 6hr. Dilute NaOH is δ added to the cooled reaction mixture to adjust the pH to 10, and the resultant solution is extracted with EtOAC/THF (1 :1 ). The organic layer is concentrated in vacuo and purified by flash chromatography using 1δ% EtOH in CH2CI2 and recrystallized from CH2CI2/ hexane to give the title compound, a solid, mp 133-134°C. 0 Example 34: δ'-Methyl-3'-(phenylmethyl)-spiro[cyclopentane- 1 ,7 , (8'H)-(3'H)-imidazo[2,1 -b]purin]-4'(δ'/-/)one El MS: M+=33δ By uε«ng 2-(1-hydroxymethylcyclopentylamino)-1-methyl-7- (pherι/lmethyl)purin-6-one in accordance with Example 1 , the title compound, an off-white solid, is obtained. Example 34a: 2', 5'-Dimethyl-3'-(phenylmethyl)- spiro[cyclopentane-1 ,7'(8Η)-(3Η)-imidazo[2,1-b]purin]-4 , (δ , fy)one El MS: M+=349 By using 2-(1-hydroxymethylcyclopentylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one in accordance with the procedure of Example 1 , the title compound, an off-white solid, is obtained. Example 3δ: cis-δ,6a(R), 7, 8, 9, 9a(S)-Hexahydro-δ-methyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)one, mp 145- By using 2-(2(R)-hydroxy-1 (R)-cyclopentylamino)-1-methyl-7- (phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 36: cis-3-Cyclopentyl-5,6a, 7, 8, 9, 9a-hexahydro-2,δ- dimethylcyclopent[4,δ]imi one CI MS: M+1=314. By using cis-3-cyclopentyl-δ,6a,7,8,9,9a-hexahydro-δ-methyl- cyclopent[4,δ]imidazo[2,1-b]purin-4(3 -/)one and 2.5 eq. of methyl iodide as the electrophile in accordance with Example 25, the title compound is obtained. Example 37 In accordance with Preparative Example 25, treat the appropriate aminoalcohols with SOCI to generate the following cyclic products: 37A1 5'-Methyl-2'-trifluoromethyl-3'- (phenyimethyl)spiro{cyclo-pentane-1 ,7'(8'H)-(3'H)imidazo[2,1-b]purin}- 4'(5'H)-one: white solid, FAB MS: M+=404. 37A2 7,8-Dihydro-δ,7,7-trimethyl-2-trifluoromethyl-3- (phenylmethyl)-3H-imidazo[2,1-b]purin-4(δW)-one: white solid, CI MS: M+1=378. 37A3 (+/-)-cis-5,6a,7,8,9,9a-Hexahydro-δ-methyl-2- trifluoromethyl-3-(phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)- one. To a solution of the title aminoalcohol of Preparative Example 25 (0.9g= 2.2mmol) in 40ml CH 2 Cl2 add SOCI 2 (0.7ml=9.2mmol). Stir at room temperature overnight. Wash the diluted solution with cold 2N NaOH, then water. Dry and solvent strip the organic layer. Chromatograph the residue, eluting with 2% CH 3 OH in CH CI 2 to give the title compound, 0.61 g white solid. CI MS: M+1=390. Example 38 (+,-) 6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,5-dimethyl-3-( phenylmethyl)-3H-pentaleno[ 6a',1':4,δ] imidazo[2,1-b] purin-4(5H)-one CI MS : M+1=376 Treat the title compound from Preparative Example 29 with SOCI2 in accordance with Preparative Example 1 to obtain the title compound. The title compound is resolved by HPLC using a chiral stationary phase (Daicel Chiralcel OD) to give the (+) and (-) isomers of the title compound, as described in Examples 39 and 40. Example 39 (+) 6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,δ-dimethyl-3- phenylmethyl-3H-pentaleno[ 6a',1 ':4,δ] imidazo[2,1 -b] purin-4(δH)-one CI MS : M+1=376 The title compound of Example 38 is resolved by HPLC using a chiral stationary phase ( Daicel Chiralcel OD). Elute with 0 0.1 :20:80 diethylamine:2-propanol:hexane to give the title compound as a solid. Example 40 (-)-6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,δ-dimethyl-3- phenylmethyl-3H-pentaleno[6a',1 ':4,δ] lmidazo[2,1 -b] purin-4(δH)-one δ CI MS : The title compound of Example 38 is resolved by HPLC using a chiral stationary phase (Daicel Chiralcel OD). Elute with 0.1 :20:80 diethylamine:2-propanol:hexane to give the title compound as 0 a solid. Example 41. (+/-) 6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,5-dimethyl- 3H-pentaleno[ 6a',1':4,δ] imidazo[2,1-b] purin-4(δH)-one, hydrochloride FAB MS : M+1= 286 O H ^- CH 3 .HCI N he title co - Racemic Treat t mpound (0.86g) from Example 38 in EtOH (80ml) containing cone HCI (0.7ml) with 20% Pearlman's catalyst ( 1.0 g, and H 2 ( 60 PSI) . After 48 hr, filtered through celite and concentrate to dryness. The residue is dissolved in water and lyophyllized to give the title compound as a colorless powder. Example 41a (+)-6a,7,8,9,9a,10,11,11 a-Octahydro-2,δ-dimethyl- 3H-pentaleno[ 6a',1':4,δ] imidazo[2,1-b] purin-4(δH)-one, hydrochloride [α]D = +114.3 (3mg/ml EtOH) FAB MS : M+1= 286 O H CH3 (+ enantiomer) Treat the title compound from Example 39 in accordance with Example 41 to obtain the title compound as a colorless powder. Example 41b (-)-6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,δ-dimethyl- 3H-pentalenG;3a',1':4,δ] imidazo[2,1-b] purin-4(δH)-one, hydrochloride [α]D = -122 (1.7mg/ml MeOH) FAB MS : M+1 = 286 Treat the title compound from Example 40 in accordance with Example 41 to obtain the title compound as a colorless powder. Example 42 (3-Phenylmethyl)-6a,7,8,9,10,10a,11 ,12,13,13a- decahydro-2,δ-dimethyl-napth[1 ,8a-d]imidazo[2,1 -b]purin-4(δH)one El MS: M+=403 Treat the title compound from Preparative Example 31 with SOCI2 in accordance with Preparative Example 1 to give the title compound. Example 43 7(R)-cyclohexyI-7,8-dihydro-2,δ-dimethyl-3- (phenylmethyl)-3H-imidazo[2,1-b]purin-4(3H)-one: solid, CI MS M+1=378 Treat 2-[2-hydroxy-1 (R)-(cyclohexyl)ethylamino]-1-methyl- 7-(phenylmethyl)purin-6-one with triphenylphosphine dibromide in DMF at 6δ°C for 18hr. Partition the cooled reaction mixture between water and ethyl acetate. Treat the aqueous phase with dilute sodium hydroxide and extract with ethyl acetate: THF 1 :1. Concentrate the organic layer and purify by silica gel chromatography using 6% ethanol in dichloromethane to give the title compound as a beige solid. Example 44 7(R)-cyclohexyl-7,8-dihydro-2,δ-dimethyl-3H- imidazo[2,1-b]purin-4(δH)-one hydrochloride: solid, FAB MS M+1=288, Treat the title compound in Example 43 with Pearlman's catalyst in accordance with Example 41 to give the title compound as a powder. Example 45 7(S)-Cyclohexyl-7,8-dihydro-2,δ-dimethyl-3- (phenylmethyl)-3H-imidazo[2,1-b]purin-4(3H)-one: solid, El MS M+=377, δ Treat 2-[2-hydroxy-1- (S)-(cyclohexyl)ethylamino]-1- methyl-7-(phenylmethyl) purin-6-one with triphenylphosphine dibromide in accordance with Example 43 to give the title compound as a solid Example 46 7(S)-Cyclohexyl-7,8-dihydro-2,δ-dimethyl-3H- 0 imidazo[2,1-b]purin-4(δH)-one hydrochloride: solid, FAB MS M+1=288, [ α ] D 20.5 = .53.1 o ( CH 3 OH) Treat the title c oompound from Example 4δ with Pearlman's catalyst in accordance with Example 41 to give the title compound as a δ powder. Example 47 δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3-[ (trimethylacetoxy)methyl]-cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one: solid, FAB MS M+1 =360 Treat δ,6a(R),7,8,9,9a(S)-hexahydro-2,δ-dimethyl- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one from Example 19a (0.28g, 1.1 mmol) in DMF with (4ml) with potassium carbonate (0.24g) and chloromethylpivalate (0.2ml, 1.4mmol) at 3δ°C for 6 hr. Cool and filter the reaction mixture. Partition the filtrate with brine and ethyl acetate: THF 1 :1. Dry and concentrate the organic layer to give the title compound as a powder. 0 Example 48 5,6a(R),7,8,9,9a(S)-Hexahydro-2,5-dimethyl-3-(4- pyridylmethyl)-cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one: solid, CI MS δ Treat δ,6a(R),7,8,9,9a(S)-hexahydro-2,δ-dimethyl- cyclopent[4,δ]imidazo[2,1-bjpurin-4(3il)-one from Example 19a with 4- chloromethyl pyridine in accordance with Example 47 to give the title compound as a powder. 0 - δO Example 49 δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3-[2-(1- moφholinyl)ethyl]cyclopent[4,5]imidazo[2,1 -b]purin-4(3H)-one: solid, CI MS M+1=3δ9, mp 144-14δ°C. Treat δ,6a(R),7,8,9,9a(S)-hexahydro-2,δ-dimethyl- cyclopent[4,δ]imidazo[2,1-b]purin-4(3JH)-one from Example 19a with 4- (2-chloroethyl)-morpholine in accordance with Example 47 to give the title compound as a powder. Example 50 5,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3- [acetoxymethyl]cyclopent[4,δ]imidazo[2,1 -b]purin-4(3H)-one: solid, CI MS M+1=318, mp 144-14δ°C. CH 3 « fc C " 1 enantiomer Treat δ,6a(R),7,8,9,9a(S)-hexahydro-2,δ-dimethyl- δ cyclopent[4,δ]imidazo[2,1-b]purin-4(3JH)-one from Example 19a with bromomethyl acetate in accordance with Example 47 to give the title compound as a powder. - δ1 Example 51 δ,6a,7,8,9,9a-Hexahydro-2,δ,6a-trimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1 -b]purin-4(3H)-one: beige solid, By using 2-(2β-hydroxy-1 β-methylcyclopentylamino)-1 ,8- dimethyl-7-(phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example δ2 δ,6a(f?),7(S),8,9,9a-Hexahydro-2,δ,6a-trimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one: yellow solid, mp 193-δ°, [α] D 23 = +38.0° (EtOH). The compound of Example δ1 is separated into the individual enantiomers by HPLC (Daicel chiralcel OD, 80:20:0.1 hexane- isopropanol-diethylamine). The (+)-enantiomer is eluted second. The title compound is also obtained from 2-(2( ?)-hydroxy-1 (/=?)- methylcyclopentylamino)-1 ,8-dimethyl-7-(phenylmethyl)purin-6-one in accordance with Example 1. Example 53 5,6a(S),7(fl),8,9,9a-Hexahydro-2,δ,6a-trimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one]: yellow solid, mp 194-6°. [α] D 23 = -38.1° (EtOH). δ2 The chiral chromatography described in Example δ2 yields the (-)-enantiomer as the first component eluted. δ Example δ4 c/s-6a,7,8,9,10,10a-Hexahydro-2,δ,7-trimethyl-3- (phenylmethyl)-3H-benzimidazo[2,1-b]purin-4(δH)-one]: tan solid, mp 1δ9-60°. By using 2-(2β-hydroxy-1 β-methylcyclohexylamino)-1 ,8- 0 dimethyl-7-(phenylmethyl)purin-6-one in accordance with Example 1 , the title compound is obtained. Example 55 c/s-5,6a,7,8,9,9a-Hexahydro-2,δ,6a- trimethylcyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one] hydrochloride: δ By using c/s-δ,6a,7,8,9,9a-hexahydro-2,δ,6a-trimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1 -b]purin-4(3H)-one] in accordance with Example 18, the title compound is obtained. - δ3 Example δ6 c/s-6a,7,8,9,10,10a-Hexahydro-2,δ,7-trimethyl-3H- benzimidazo[2,1-b]purin-4(δH)-one]: beige solid, mp 262-4°. By using c/s-6a,7,8,9,10,10a-hexahydro-2,δ,7-trimethyl-3- (phenylmethyl)-3H-benzimidazo[2,1 -b]purin-4(δH)-one in accordance with Example 18, the title compound is obtained. 0 Preparation of Starting Materials The starting materials of formulas (II) and (XX) are well known in the art, as taught, for example, in Weissberger, Pyrimidines, supra and Weissberger, Purines, supra. δ The following preparative examples illustrate various methods for preparing starting materials used to make the present invention. Preparative Example 1 : 6-Amino-3-meinyl-5 0 6-amino-3-met !-5-nitroso ; ,? imidine-2,4-dione (37.5g=0.22mol) with 10% palladium on carbon (Pd/C) (1.9g) and 25% NaOH (25ml) in 0.75L water. Hydrogenate at δ0 psi for 3hr, filter through Celite, and dilute to 1.δL with water. Adjust to pH 4.δ with HOAc and add benzaldehyde δ (3δg=0.34mol). Add O.δ kg ice, collect ιe solid, wash with water, then acetonitrile, and dry to give the title compound as a yellow powder. - δ4 Preparative Example 2: 6-Amino-3-methyl-δ- (phenylmethylamino)pyrimidine-2,4-dione δ Add 6-amino-3-methyl-δ-(phenylmethyleneamino)pyrimidine-2,4-dione (8δg=0.3δmol) to CH 2 CI 2 (1.6L) and MeOH (1.6L). Stir the suspension, add HOAc (21.9ml=0.3δmol), then NaCNBH 3 (21.9g=0.3δmol). Stir l.δhr, and add HOAc (2ml) and NaCNBH 3 (2.0g). After another 30min, concentrate to ca. 1.6L on a rotovap (3δ°C bath). Chill the crystalline 0 mixture, filter, and wash with cold MeOH. Stir the product Iδmin in O.δL boiling MeOH, chill, filter, and dry to obtain the title compound, m.p. 206- 218°C. To 6-amino-3-methyl-δ-(phenylmethylamino)pyrimidine-2,4-dione (24.6g=0.1mol) in DMF (12δml) at 60°C add triethyl orthoformate (7δml=0.4δmol). Heat to 110°C for δhr, cool in ice, filter, and wash with methanol, then ether, to obtain the title compound, m.p. 268-71 °C. 0 In a similar manner employ the appropriate orthoester to obtain the following 8-substituted products: 3A 1 ,8-Dimethyl-(7-phenylmethyl)purine-2,6-dione: white solid, m.p. 293-δ°C- 3B 8-Ethyl-1 -methyl-7-(phenylmethyl)purine-2,6-dione: δ pale yellow solid, CI MS: M+1=28δ. 3C 1 -Methyl-8-phenyl-7-(phenylmethyl)purine-2,6-dione: white solid, CI MS: M+1=333. δ Preparative Example 4: 2-Chloro-1 -methyl-7-(phenylmethyl)purin-6-one Heat 1-methyl-7-(phenylmethyl)purine-2,6-dione (8.0g=31 mmol) in POCI3 (80ml) at reflux 7hr. Concentrate in vacuo, partition EtOAc-ice δ water, wash with water, dry and concentrate. Chromatograph on silica with 98:2 CH CI 2 /MeOH to obtain the title compound as a foam, FAB MS: M+1=27δ. Similarly, convert the other materials of Preparative Example 3 into the corresponding chloro-compounds: 0 4A 2-Chloro-1 ,8-dimethyl-7-(phenylmethyl)purin-6-one: off-white solid, El MS: M+1= 290. 4B 2-Chloro-8-ethyl-1 -methyl-7-(phenylmethyl)purin-6- one: white solid, FAB MS: M+=303. 4C 2-Chloro-1 -methyl-8-phenyl-7-(phenylmethyl)purin-6- δ one: white crystals, CI MS: M+1 = 3δ1. Preparative Example 5: 2-(trans-2-Hydroxycyclopentylamino)-1 -methyl- 7-(phenylmethyl)purin-6-one 0 Heat at reflux for 2 days a mixture of 2-chloro-1-methyl-7- (phenylmethyl)purin-6-one (3.14g=11.4mmol), triethylamine (1.7g=16.8mmol), and (±)-trans-2-aminocyclopentanol (4.04g=39.9mmol) in CH3CN (1δ0ml). Collect the precipitate, wash with water, and dry to give the title compound, a solid, FAB MS: M+1=340. δ Similarly, treat a chloro-compound of Preparative Example 4 with the appropriate amino-alcohol to obtain the following hydroxyalkylamino-purines: δ6 δ.1 2-(2-hydroxyethylamino)-1 -methyl-7- (phenylmethyl)purin-6-one: white solid, FAB MS: M+1=300. 5.2 2-(trans-2-hydroxycyclohexylamino)-1 -methyl-7- (phenylmethyl)purin-6-one: white solid, FAB MS: M+1=3δ4. δ δ.3 2-(3-hydroxypropylamino)-1-methyl-7- (phenylmethyl)purin-6-one: white solid, FAB MS: M+1=314. δ.4 2-(2-hydroxy-2-phenylethylamino)-1 -methyl-7- (phenylmethyl)purin-6-one: white solid, FAB MS: M+1=376. δ.δ 2-(1 -(hydroxycyclohexyl)methylamino)-1 -methyl-7- 0 (phenylmethyl)purin-6-one: white solid, CI MS: M+1=368. δ.6 2-(2-hydroxy-1 -indanylamino)-1 -methyl-7- (phenylmethyl)purin-6-one: off-white solid, CI MS: M+1=388. δ.7 2-(1 -hydroxy-2-indanylamino)-1 -methyl-7- (phenylmethyl)purin-6-one: off-white solid, CI MS: M+1=388. δ δ.8 2-(1-hydroxymethylcyclopentylamino)-1-methyl-7- (phenylmethyl)purin-6-one: white solid, CI MS: M+1=3δ4. δ.9 2-(trans-2-hydroxycyclopentylamino)-1 ,8-dimethyl- 7-(phenylmethyl)purin-6-one : white solid, CI MS: M+1=3δ4. δ.10 (+)-isomer : 2-(2(fl)-hydroxy-1 (f?)-cyclopentylamino)- 0 1 ,8-dimethyl-7-(phenylmethyl)purin-6-one : white solid, CI MS: M+1=3δ4, MD 5 = +8.3°. 5.11 (-)-isomer: 2-(2(S)-hydroxy-1(S)-cyclopentylamino)- 1 ,8-dimethyl-7-(phenylmethyl)purin-6-one: white solid, El MS: M+=353, M 6 = -8.20. δ δA2 2-(trans-2-hydroxycyclohexylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one: white solid, CI MS: M+1=368. δAδ 2-(1 -(hydroxycyclohexyl)methylamino)-1 ,8-dimethyl- 7-(phenylmethyl)purin-6-one: white solid, CI MS: M+1=382. δA9 2-(trans-2-hydroxycycloheptylamino)-1 ,8-dimethyl-7- 0 (phenylmethyl)purin-6-one: white solid, CI MS: M+1=382. δA10 2-(1 -hydroxymethylcyclopentylamino)-1 ,8-dimethyl- 7-(phenylmethyl)purin-6-one: off-white solid, FAB MS: M+1=368. δA11 2-(1 -hydroxy-2-methyl-2-propylamino)-1 ,8-dimethyl- 7-(phenylmethyl)purin-6-one: off-white solid, FAB MS: M+1=341 - δ7 δA12 2-(1 (R)-phenyl-2-hydroxyethylamino)-1 ,8-dimethyl- 7-(phenylmethyl)purin-6-one: colorless foamed solid, CI MS: M+1=390. [ α ] D 26 = +29.2°. δA13 2-(1 -phenyl-3-hydroxy-2(R)-propylamino)-1 ,8- δ dimethyl-7-(phenylmethyl)purin-6-one: CI MS: M+1=404. [α]o 26 = +80.1°. δA14 2-(1 -hydroxy-2(R,S)-butylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one: off-white foamed solid. Thin layer chromatography (10% CH 3 OH in CH 2 CI 2 ): one spot, Rf= O.δ. 0 5A1δ 2-((1 S,2S)-2-hydroxycyclohexylamino)-8-dimethyl- 7-(phenylmethyl)purin-6-one: white foamed solid, CI MS: M+1=368. [α] D 6=+20.9°. δA16 2-((1 R,2R)-2-hydroxycyclohexylamino)-1 ,8-dimethyl- 7-(phenylmethyl)purin-6-one: white foam, CI MS: M+=368. [α]o 26 =- δ 21.4°. δA17 (+)-isomer: 2-(1-hydroxy-3-methyl-2-butylamino)- 1 ,8-dimethyl-7-(phenylmethyl)purin-6-one: CI MS: M+=3δ6. [α] D 2 4=+δ7°. δA18 (-)-isomer: 2-(1-hydroxy-2-propylamino)-1 ,8- 0 c : -nethyl-7-(phenylmethyl)purin-6-one: white solid, CI MS: M+=327.[ αS D 26 =-1.9°. δAI 9 2-(trans-2-hydroxycyclopentylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one: tan solid, El MS: M+=367. δA20 (-)-isomer: 2-(1-hydroxy-3-methyl-2-pentylamino)- δ 1 ,8-dimethyl-7- ρhenylmethyl)purin-6-one: white solid, FAB MS: M+1=370. [α[ D 26 =-52.1°. 5A21 (+)-isomer: 2-(1-hydroxy-4-methyl-2-pentylamino)- 1 ,8-dimethyl-7-(phenylmethyl)p rin-6-one: white so 1, FAB MS: M+1=370. [α] D 2δ =+43.7°. 0 δA22 2-(1-methoxycarbonyl-2-hydroxyethylamino)-1 ,8- dimethyl-7-(phenylmethyl)purin-6-one: tan solid, El MS: M+=371. δA23 2-(1 -hydroxy-2-pentylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one: off-white solid, CI MS: M+1=3δ6. 5A24 (-)-isomer: 2-(1-hydroxy-3-methyl-2-butylamino)-1 ,8- dimethyl-7-(phenylmethyl)purin-6-one: white solid, El MS: M+=355. 5A2δ 2-(2-methyl-3-hydroxy-2-butylamino)-1 ,8-dimethyl-7- (phenylmethyl)purin-6-one: tan foam, CI MS: M+=3δδ. δ δA26 2-(2-methyl-4(R,S)-hydroxy-2-pentylamino)-1 ,8- dimethyl-7-(phenylmethyl)purin-6-one: off-white solid, FAB MS: M+1=370. δA27 2-[2-hydroxy-1 (R)-(cyclohexyl)ethylamino]-1-methyl- 7-(phenylmethyl)purin-6-one, solid [OC]D 23 - 5 = -IO.8° ( CH3OH) 0 δA28 2-[2-hydroxy-1 (S)-(cyclohexyl)ethylamino]-1-methyl- 7-(phenylmethyl)purin-6-one, solid, +12.1 ° ( CH3OH) δB 2-(trans-2-hydroxycyclopentylamino)-8-ethyl-1 - methyl-7-(phenylmethyl)purin-6-one: white solid, CI MS: M+1=368. δB2 2-(trans-2-hydroxycyclohexylamino)-8-ethyl-1-methyl- 7-(phenylmethyl)purin-6-one: white solid, FAB MS: M+1=382. δC 2-(trans-2-hydroxycyclopentylamino)-1 -methyl-8- phenyl-7-(phenylmethyl)purin-6-one: white solid, CI MS: M+1=416. δC2 2-(trans-2-hydroxycyclohexylamino)-1 -methyl-8- 0 phenyl-7-(phenylmethyl)purin-6-one: white solid, FAB MS: M+1=430. δC3 2-(2(R)-hydroxy-1 (R)-cyclopentylamino)-1 -methyl-7- (phenylmethyl)purin-6-one; mp 1δ8-160°C Preparative Example 6: 6-Amino-3-(phenylmethyl)-2- δ methylthiopyrimidin-4-(3H)-one To a slurry of 60% NaH dispersion (1.8 g = 4δ mmol) in 25 ml DMF at 10°C. add dropwise a solution of 6-amino-2-methylthio-4-hydroxypyrimidine (6.3 g = 40 mmol) in 150 ml DMF. When gas evolution subsides, add benzyl 0 bromide (7.5 g = 44 mmol). Stir 1.δ hr. at room temperature. Remove DMF and partitition the residue between EtOAc and water. Wash the organic δ9 layer with water, dry and concentrate. Recrystallize the residue from CH3CN to give the title compound, a white solid. FAB MS: M+1=248. Preparative Example 7: 6-Amino-3-(phenylmethyl)pyrimidine-2,4-dione Reflux 6-amino-3-(phenylmethyl)-2-methylthiopyrimidin-4(3H)-one (2.δ g 10 mmol) in 40 ml 10% aqueous NaOH for four hours. Cool, acidify the solution and collect the precipitate. Water wash and dry to give the title compound, a white solid, El MS: M+ = 217. Preparative Example 8: 6-Amino-3-(phenylmethyl)-δ-nitrosopyrimidine-2,4- dione Slurry 6-amino-3-(phenylmethyl)-pyrimidine-2,4-dione (1.1 g = δ mmol) in δO ml water. Add NaN0 2 (0.63 g = 9.1 mmol), warm to 7δ°C and add acetic acid (2.6 ml = 4δ mmol) in 30 ml water over two hours. Collect the product, water wash and dry over P2O5 to give title compound as an orange solid. El MS: M+ = 246. Preparative Example 9: 6-Amino-3-(phenylmethyl)-δ- (phenylmethyleneamino)pyrimidine-2,4-dione H Treat 6-amino-3-(phenylmethyl)-δ-nitrosopyrimidine-2,4-dione according to Preparative Example 1 to obtain the title compound, a yellow solid. El MS: M+=320. Preparative Example 10: 6-Amino-3-(phenylmethyl)-δ- Reduce 6-amino-3-(phenylmethyl)-δ-(phenylmethyleneamino)pyrimidine according the the procedure of Preparative Example 2 to give the title 0 compound, a white solid. CI MS: M+=322. Preparative Example 11 : 1 ,7-Bis(phenylmethyl)purin-2,6-dione Cyclize 6-amino-3-(phenylmethyl)-δ-(phenylmethylamino)pyrimidine-2,4- δ dione in accordance with Preparative Example 3 to give the title compound, a tan solid. CI MS: M+1=333. Preparative Example 12: 2-chloro-1 ,7-bis(phenylmethyl)purin-6-one 0 Treat 1 ,7-bis(phenylmethyl)purin-2,6-dione with POCI3 in accordance with Preparative Example 4, to give the title compound, an off-white solid, El MS: M+=3δ0. Preparative Example 13: 2-(trans-2-Hydroxycyclopentylamino)-1 ,7- bis(phenylmethyl)purin-6-one Treat 2-chloro-1 ,7-bis(phenyimethyl)purin-6-one with trans-2- δ aminocyclopentanol as described in Preparative Example δ to give the title compound, a tan solid. FAB MS: M+1=416. Preparative Example 14: 2-(trans-2-Hydroxycyclohexylamino)-1 ,7- bis(phenylmethyl)purin-6-one 0 Treat 2-chloro-1 ,7-bis(phenylmethyl)purin-6-one with trans-2- aminocyclohexanol as described in Preparative Example δ to give the title compound, a tan foam. FAB MS: M+1=430. Preparative Example 15: 2-Chloro-6-benzyloxypurine 2,6-dichloropurine (0.30g,1.6mmol) is added to a mixture of benzyl alcohol (0.19g, 1.8mmol) and 60% sodium hydride (0.13g, 3.3mmol) in 0 DMF (8ml) at room temperature (RT). After 1 hr, the reaction is heated to 60°C for 18 hr, cooled to RT and dilute HCI is added to adjust the pH to δ. The mixture is extracted with EtOAc/THF 1 :1 , and the organic layer is dried over sodium sulfate, filtered and concentrated to give a solid. This is recrystallized from EtOAc/ hexane to give the title compound, mp. 19δ- δ 196°C. Preparative Example 16: 2-Chloro-6-benzyloxy-7-cyclopentylpurine and 2-Chloro-6-benzyloxy-9-cyclopentylpurine A mixture of 2-chloro-6-benzyloxypurine (0.32g,1.2 mmol) cyclopentyl mesylate (0.24g) and K C0 3 (0.2δg, 1.8 mm) in DMF (10ml) is heated to δ 7δ°C for 18hr. The mixture is cooled to RT and partitioned between brine and EtOAc/THF 1 :1. The organic phase is concentrated in vacuo to give a solid, which is purified by flash chromatography. Elution with 40% EtOAc in hexane gives the N-9 isomer of the title compound as a solid FAB MS : M+1= 329. Further elution gives the N-7 isomer of the title 0 compound, a solid. FAB MS : M+1= 329. Preparative Example 17: 2-Chloro-7-cyclopentylpurin-6-one and 2- Bromo-7-cyclopentylpurin-6-one 2-Chloro-6-benzyloxy-7-cyclopentylpurine (1.0 g, 3mmol) is treated with 33% HBr in acetic acid (2δml). After 1 hr at RT, the mixture is 0 concentrated in vacuo and triturated with H2O and hexane to give a mixture of the title compounds, a solid. CI MS M+1=28δ,283 and 241 ,239. Preparative Example 18: 1 -Methyl-2-chloro-7-cyclopentylpurin-6-one δ and 1-Methyf-2-bromo-7-cyclopentylpurin-6-one lodomethane (0.95 ml) is added to a mixture of 2-chloro-7- cyclopentylpurin-6-one and 2-bromo-7-cyclopentylpurin-6-one (1.8g) and LiOH (0.38g) in DMF (20ml) at 0°C. After 1 hr at RT, the mixture is partitioned between EtOAC/THF (1 :1), and brine. The organic layers are concentrated in vacuo and the residue is purified by flash chromatography using 3% EtOH in CH 2 CL2 to give a mixture of the title compounds, a solid, mp 140-14δ°C . Preparative Example 19: 2-Chloro-9-cyclopentylpurin-6-one and 2- Bromo-9-cyclopentylpurin-6-one Treat 2-chloro-6-benzyloxy-9-cyclopentylpurine with HBr in acetic acid as described in Preparative Example 17 to give a mixture of the title compounds as a solid. CI MS M+1 = 28δ, 283 and 241 ,239. Preparative Example 20: 1 -Methyl-2-chloro-9-cyclopentylpurin-6-one and 1 -methyl-2-bromo-9-cyclopentylpurin-6-one Treat 2-chloro-9-cyclopentylpurin-6-one and 2-bromo-9- cyclopentylpurin-6-one with methyl iodide as described in Preparative δ Example 18 to give a mixture of the title compounds, a solid. CI MS M+1= 299, 297 and 2δδ, 2δ3. Preparative Example 21 6-Amino-3-methyl-δ-(N- (phenylmethyl)trifluoracetamido)-pyrimidine-2,4-dione. 0 Add amine from Preparative Example 2 (1.23g=δmmol) to a mixture of 1.0ml trifluoroacetic anhydride and 10ml trifluoroacetic acid. Reflux overnight. Cool, pour into cold water, collect and water wash the precipitate to give, after drying, 1 ,4δg of the title compound. One spot on thin layer chromatography; FAB MS: M+=342. 5 Preparative Example 22 1-Methyl-7-(phenylmethyl)-8- trifluoromethylpurine-2,6-dione. To the trifluoroacetamide (3.4g=10mmol) of Preparative Example 21 , in 50ml DMF add sodium methoxide (2.7g=50mmol) , and 0 heat the mixture, at 130-1 δ0° for 3 hours. Pour into water, acidify, collect and dry the precipitate to give 2.δg of the title compound, m.p. 211-213°. CI MS: M+1=32δ. Preparative Example 23 2-Chloro-1 -methyl-7-(phenylmethyl)-8- δ trifluoromethylpurin-6-one. Reflux the trifluoromethylpurine of Preparative Example 22 (10.0g=31mmol) in 100ml POCI3 10 hours. Remove excess reagent in vacuo, and partition the residue between ice water and ethyl acetate (EtOAc). Wash the the organic layer, dry, and remove solvent. Chromatograph on silica; elute with 2% CH 3 OH in CH2CI2 to give δ.1g of the title compound. Tan solid, CI MS:M+1=343. Preparative Example 24 (+/-)-2-(trans-2-Hydroxycyclopentylamino)-1 - δ methyl-7-(phenyimethyl)-8-trifluoromethylpurin-6-one. Heat under reflux a mixture of the chloropurine of Preparative Example 23 (0.86g=2.δmmol), (+/-)-trans-2-aminocyclopentanol (1.01g=10mmol), and triethylamine (0.6ml=4.3mmol) in 10 ml CH 3 CN overnight. Remove solvent, partition residue between water and EtOAc. Dry the organic 0 layer, remove solvent, and chromatograph the product on silica. Elution with δ% CH3OH in CH CI 2 gives 0.91 g title compound. Tan foam, FAB MS: M+1=408. δ Preparative Example 25 2-(1-hydroxymethylcyclopentylamino)-1- methyl-7-(phenylmethyl)-8-trifluoromethylpurin-6-one: tan foam, CI MS: M+1=422. Treat the chloropurine of Preparative Example 23 with the appropriate amino alcohol to give the title compound. Similarly prepare: 0 2δ.1 2-(1-hydroxy-2-methyl-2-propylamino)-1-methyl-7- (phenylmethyl)-8-trifluoromethylpurin-6-one: white foam, CI MS: M+1=396. Preparative Example 26 2-[2-(2-Nitrocyclopentyl)ethyl]-1 ,3-dioxane NO 2 δ At -78°C, add 1 -nitrocyclopentene ( 1.8ml~, 18-.4m Q mol) in THF (20ml) to a THF solution (33m f the zinc-copper reagent prepared from 2-(2- iodoethyl)-1 ,3-diox ^ (δ.6gm,2&; n), zinc powder (1.58 g), CuCN (1.9 g) and LiCI (1.7 g) , according to the general procedure of P. Knochel et. 0 al. (J. Org. Chem. 1989, 54, 5200). After 15min. warm to 0°C for one hour, then recool to -78°C and add AcOH (2.0 ml). Warm to RT, add AcOH:0.1 N HCI (15ml, 1 :2) and stir for one hr. Partition between EtOAc and 9rine. Concentrate the organic layer and purify by silica gel chromatography using EtOAc/Hex 1 :3 to elute the title compound (3.6g 15.7mmol) as an oil. CI MS : M+1 =230. Preparative Example 27 1 -Hydroxy-7-nitrobicyclo[3.3.0]octane δ Add toluenesulfonic acid (0.1 g) to a dry MeOH (200ml) solution of the title compound (3.6 g) from Preparative Example 6. Heat to reflux for 6 hr. then cool to room temperature, add NaHCθ3 (0.1 g) and concentrate 0 to dryness. Dissolve the residue in THF (60ml) and O.δN HCI (30ml). After 13hr, remove the THF in vacuo and partition the residue with Et2θ and brine. Dry the Et2θ layer (MgS04), and concentrate. Dissolve the residue (2.0g) in MeOH ( δOml) and add anhyrdous K2CO3 (0.14g ). After seven hours add AcOH (0.1 δml) and concentrate to dryness. δ Dissolve the residue in Et2θ and wash with brine. Usual workup of the Et2θ layer affords the title compound (2.0 g) CI MS : M+1= 172 Preparative Example 28 1 -Hydroxy-7-aminobicyclo[3.3.0]octane Dissolve the title compound from Example 2 ( 2.8 g) in EtOH (40ml), add this to Raney nickel ( 2 g, wet weight ) and place under H2 at 60 psi. After 48 hr, filter through celite and concentrate the filtrate to dryness. Dissolve the resultant oil ( 2.7 g) in Et2θ. To this add a solution of dry δ HCI in MeOH and collect the title compound as a colorless solid. El MS M+ = 141 Preparative Example 29 2-(1-Hydroxybicyclo[3.3.0]octyl-7-amino)-1 ,8- dimethyl-7-(phenylmethyl)purin-6-one Heat a mixture of the title compound from Preparative Example 28 (10.8g, 60.8mmol ) , 2-chloro-1-methyl-7(phenylmethyl)purin-6-one ( 21.δg , 74.4mmol) and diisopropylethylamine (40ml) in 1-methyl-2- δ pyrrolidinone (3δml) to 140°C for 64hr. Cool the mixture and pour into ice water. Collect the resultant precipitate (22g) and purify this by silica gel chromatography using CH2CI2: EtOH (90:10) to obtain the title compound (14.2 g) as a solid. CI MS M + 1 = 394. 0 Pre p arative Example 30 1-Hydroxy-8a-nitrodecahydronapthalene hydrochloride To a solution of 8a-nitrodecahydronapthalen-1-one [ P. Dampawan and W.W. Zajac Jr. Synthesis,δ4δ,1983](1.2g, 6.1 mmol) in δ MeOH (10ml) at 0°C , add sodium borohydride (.09g) and warm to RT. After O.δhr, add ether and 1 N HCI. Dry and concentrate the organic layer. Dissolve the residue in EtOH (δO ml) and add this to Raney Nickel ( 1.2g, wet weight) and place under 60 psi of H2 at δδ°C. After 24 hr. , filter though celite and concentrate to dryness. Dissolve the resultant oil 0 in Et2θ add dry HCI in MeOH and collect the title compound as a colorless precipitate El MS : M+= 169. Preparative Example 31 2-(1 -Hydroxydecahydronapthalen-8a- ylamino)-1 ,8-dimethyl-7-(phenylmethyl)purin-6-one: FAB MS : δ M+1=422 Treat the title compound in Preparative Example 30 with 2-chloro-1 ,8- dimethyl-7-(phenylmethyl)purin-6-one in accordance with Preparative δ Example 29 to give the title compound. Preparative Example 32. 2β-Amino-2α-methylcyclopentanol A. To methyl 1-methy!-2-oxocyclopentanecarboxylate (20.0g=128mmol) in THF (800ml) add portionwise lithium tri-f- 0 butoxyaluminohydride (40.7g=160mmol). Stir 1hr and partition between Et 0 and 1.0N HCI. Dry and concentrate to obtain methyl 1-methyl-2- hydroxycyclopentanecarboxylate, largely the 1 β-methyl-2β-hydroxy isomer, as an oil. B. Combine the above ester with 2δ0ml each 1.ON NaOH and δ MeOH. After 24hr, concentrate and partition with EtOAc and 1.ON HCI (saturated with NaCl). Dry and concentrate to obtain 1-methyl-2- hydroxycyclopentanecarboxylic acid, largely the 1β-methyl-2β-hydroxy isomer, as a wet solid. C. Combine the above acid (δ.00g=34.7mmol) with Et 3 N 0 (3.68g=36.δmmol) and diphenylphosphoryl azide (10.0g=36.δmmol) in toluene (100ml). Heat at 80° 1 hr, allow to cool, add benzyl alcohol (3.93g=36.δmmol), and heat at reflux 18hr. Allow to cool, concentrate, and partition with EtOAc and 1.ON NaHC0 3 . Dry and concentrate to obtain an oil. Chromatograph on silica with 1 :1 Et 2 0-hexane to obtain δ 2α-methyl-2β-(phenylmethoxycarbonylamino)cyclopentanol as an oil. D. Shake the above carbamate (2.δ0g=10.0mmol) with 10% Pd/C (0.6g) in MeOH (1δ0ml) under 60psi hydrogen. After 2hr, filter and concentrate to obtain 2β-amino-2α-methylcyclopentanol as an oil. δ Preparative Example 33 1(/=?),2(ft)-2-Amino-2-methylcyclopentanol A. Treat the acid of Preparative Example 32B (10.8g) in Et 2 0 (110ml) with (fl)-(+)-α-methylbenzylamine (δ.42g) in Et 2 0 (70ml). Collect the precipitate and dissolve in a boiling mixture of 10:1 CH 2 Cl2/MeOH (400ml). Boil down to 200ml volume, allow to cool, and 0 collect the solid. Recrystallize from CH CI 2 (60ml) and MeOH (2δml) by boiling down with addition of CH 2 CI 2 (9δml) to a final volume of 60ml. Allow to cool and collect the (f?)-(+)-α-methylbenzylamine salt of 1 (/=ϊ),2(fl)-1-methyl-2-hydroxycyclopentanecarboxylic acid as a solid, mp 172-3°, [α] D 3 = -4.9° (EtOH). Partition the salt between Et 2 0 and 1.ON δ HCI. Dry and concentrate to obtain (/?),2(/?)-1-methyl-2- hydroxycyclopentanecarboxylic acid as a solid, mp 70-1°. B. Treat the above acid in analogous fashion to Preparative Example 32C to obtain 1 (fl),2(fl)-2-methyl-2- (phenylmethoxycarbonylamino)cyclopentanol as an oil. 0 C. Treat the above carbamate in analogous fashion to Preparative Example 32D to totain 1(f?),2(f?)-2-amino-2- methylcyclopentanol as an oil. Preparative Example 34 2β-Amino-2α-methylcyclohexanol δ A. Treat ethyl 1-methyl-2-oxocyclohexanecarboxylate in analogous fashion to Preparative Example 32A to obtain ethyl 1-methyl- 2-hydroxycyclohexanecarboxylate, largely the 1 β-methyl-2β-hydroxy isomer, as an oil. B. C Dmbine the above ester (4.97g=26.7mmol) with 80ml each 0 1.0N Na » and EtOH. After 48hr, concentrate and partition with EtOAc and 1.0N HCI (saturated with NaCl). Dry and concentrate ϊo obtain 1- methyl-2-hydroxycyclohexanecarboxylic acid, largely the 1 β-methyl-2β- hydroxy isomer, as a beige solid. Recrystallize from Et 2 0-hexane to obtain the pure isomer as a white solid, mp 97°. C. Combine the above acid (2.00g=12.7mmol) with Et3N (1.40g=13.9mmol) and diphenylphosphoryl azide (3.82g=13.9mmoI) in toluene (40ml). Heat at 100° 1hr, allow to cool, and concentrate. Partition with EtOAc and 1.ON NaHC0 3 , wash with water, dry and δ concentrate to obtain a solid. Recrystallize from Et2θ-hexane to obtain 3aα,4,δ,6,7,7aα-hexahydro-3aβ-methyl-2(3H)benzoxazolone as a white solid, mp 107-9°. D. Heat the above carbamate (1.10g=7.09mmol) with 20% KOH (δOml) at reflux 4hr. Allow to cool, saturate with NaCl, and extract with 0 EtOAc. Dry and concentrate to obtain 2β-amino-2α-methylcyclohexanol as a gum. Preparative Example 35 2-(2β-Hydroxy-1 β-methylcyclopentylamino)- 1 ,8-dimethyl-7-(phenylmethyl)purin-6-one δ Combine the aminoalcohol of Preparative Example 32 (1.10g=9.6mmol) and 2-chloro-1 ,8-dimethyl-7-(phenylmethyl)purin-6- one (2.7δ=9.6mmol) with N-methylpyrrolidinone (δ.Og) and diisopropylethylamine (δ.2g). Heat in a sealed vessel at 140° for 40hr, allow to cool, and partition with EtOAc and water. Dry and concentrate 0 to obtain an oil. Chromatograph on silica with 4% MeOH/CH 2 CI 2 to obtain the title compound as a foam, FAB MS: M+1=368. In similar fashion employ the aminoalcohol of Preparative Example 33 to obtain 2-(2(/?)-hydroxy-1 (fl)-methylcyclopentylamino)- 1 ,8-dimethyl-7-(phenylmethyl)purin-6-one as a foam, FAB MS: δ M+1=368. In similar fashion employ the aminoalcohol of Preparative Example 34 to obtain 2-(2β-hydroxy-1 β-methylcyclohexylamino)-1 ,8- dimethyl-7-(phenylmethyl)purin-6-one as a foam, FAB MS: M+1=382. 0 Pharmaceutical Preparations The compounds of formulas (I) and (I') can be combined with a suitable pharmaceutical carrier to prepare a pharmaceutical preparation or composition suitable for parenteral or oral administration. Such pharmaceutical compositions are useful in the treatment of cardiovascular and pulmonary disorders such as mammalian hypertension and bronchoconstriction. The effective daily antihypertensive dose (EDδO) of the present compounds will typically be in the range of about 1 to about 100 δ mg/kg of mammalian body weight, administered in single or divided doses. The exact dosage to be administered can be determined by the attending clinician and is dependent upon where the particular compound lies within the above cited range, as well as upon the age, weight and condition of the individual. 0 Generally, in treating humans in need of treatment for hypertension or bronchoconstriction, the present compounds can be administered in a dosage range of about 10 to about δOO mg per patient generally given a number of times per day, providing a total daily dosage of from about 10 to about 2000 mg per day. δ The compositions of the present invention can be administered orally or parenterally. Typical injectable formulations include solutions and suspensions. Typical oral formulations include tablets, capsules syrups, suspensions and elixirs. Also contemplated are mechanical delivery systems, e.g. transdermal dosage forms. 0 The typical acceptable pharmaceutical carriers for use in the formulations described above are exemplified by sugars such as lactose, sucrose, mannitol and sorbitol; starches such as corn starch, tapioca starch and potato starch; cellulose and derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and methyl cellulose; calcium phosphates such as dicalcium phosphate and tricalcium phosphate; sodium sulfate; calcium sulfate; polyvinylpyrrolidone, polyvinyl alcohol; stearic acid; alkaline earth metal stearates such as magnesium stearate and calcium stearate, stearic acid, vegetable oils such as peanut oil, cottonse oil, sesame oil, olive oil and com oil; non-ionic, cationic and anionic sur s ants; eth ne glycol polymers; beta-cyclodextrin; fatty alcohols and cereal solids; as well as other non-toxic compatible fillers, binders, disintegrants, buffers, preservatives, antioxidants, lubricants, flavoring agents, and the like commonly used in pharmaceutical formulations. Following are typical examples of oral and parenteral formulations, wherein the term "Active Ingredient" refers to a compound of formula (I) or (I'). A capsule comprising the Active Ingredient: (+)-6a,7,8,9,9a,10,11 ,11 a-octahydro-2,δ-dimethyl-3H-pentaleno [6a',1':4,δ] imidazo[2,1-b] purin-4(δH)-one, hydrochloride is prepared from the following ingredients: Blend the active ingredient, lactose and corn starch until uniform; then blend the magnesium stearate into the resulting powder. Encapsulate the mixture into suitably sized two-piece hard gelatin capsules. Ca sule Amount ( mg ) Active Ingredient 2δ0.0 125.0 Lactose 161.0 80.5 Corn Starch 12.0 6.0 Water (per thousand tablets) 120 ml 60 ml (evaporates) (evaporates) Corn Starch 7δ.O 37.δ Magnesium Stearate 2.0 1.0 TOTAL δOO.O 2δ0.0 Blend the active ingredient with the lactose until uniform. Blen s e smaller quantity of corn starch with the water and add the resui * . corn starch paste then mix until a uniform wet mass is formed. Add the remaining corn starch to the remainir.y wet mass and mix un Jl uniform granules are obtained. Screen the granules through a suitable milling machine, using a 3/4 inch stainless steel screen. Dry the milled granules in a suitable drying oven until the desired moisture content is obtat; ad. Mill the dried granules through a suitable milling machine using a 16 mesh stainless steel screen. Blend in the magnesium stearate and compress the resulting mixture into tablets of desired shape, thickness, hardness and disintegration. Injectable Solution mg/ml Active Ingredient 5.00 Methyl p-hydroxybenzoate 0.80 Propyl p-hydroxybenzoate 0.10 Disodium Edetate 0.10 Citric Acid Monohydrate 0.08 Dextrose 40.0 Water for injection qs. ad. 1.0 ml Dissolve the p-hydroxybenzoates in a portion of water for injection at a temperature of between 60°C - 70°C and cool the solution to 20°C - 30°C, Charge and dissolve all other excipients and the active ingredient. Bring the solution to final volume, filter it through a sterilizing membrane and fill into sterile containers. Biological Activity of Polycyclic Guanines The present compounds are useful in inhibiting the phosphodiesterase enzymes . These phosphodiesterase enzymes are known to hydrolyze cGMP in smooth muscle. High levels of cGMP are associated with the relaxation of vascular smooth muscle, with a consequent subsequent reduction in blood pressure. Thus, it is believed that by inhibiting these phosphodiesterase enzymes, cGMP levels in muscle will be either maintained or increased with a subsequent reduction in blood pressure. In vivo antihypertensive activity is determined orally in spontaneously hypertensive rats (SHR). Phosphodiesterase inhibition in vitro: Compounds are evaluated for inhibition of two phosphodiesterase enzymes which hydrolyze cyclic guanosine 5 monophosphate (cGMP). The first enzyme, calcium-calmodulin dependent phosphodiesterase (CaM-PDE), is a partially pure enzyme obtained from bovine aorta homogenates and purified by DEAE- cellulose and calmodulin-affinity chromatography. The enzyme is activated several fold by Ca-calmodulin and is selective for cGMP, 0 although it will also hydrolyze cAMP. The second enzyme, cGMP phosphodiesterase (cGMP-PDE), is a homogeneous enzyme obtained from bovine lung and purified by ion-exchange chromatography, gel filtration, and sucrose gradient centrifugation. cGMP-PDE is highly selective for cGMP. Bovine aorta homogenates and primary cultures of δ bovine aortic endothelial and vascular smooth muscle cells contain an enzyme with properties very similar to the lung isozyme. The enzyme assay is performed using a Biomek Automated Pipetting Station. Compounds are dissolved in distilled water or DMSO and diluted with 10% DMSO. Compounds are tested at 0 several concentrations at log intervals, typically 0.1 , 1.0, 10, and 100 μM final concentration. Assays contain the following components: 1 μM substrate 3 H-cGMP δO mM Tris-HCI, pH 7.δ, δ mM magnesium chloride δ (MgCI 2 ) O.δ mg/ml snake venom alkaline phosphatase 0.1 μM Calmodulin and 1 mM CaCl2 (for CaM-PDE only) Assays are initiated by addition of enzyme and stopped by addition of 10 mM isobutylmethylxanthine, a general 0 phosphodiesterase inhibitor. Assays are performed for 2δ minutes at room temperature to achieve δ-10% hydrolysis of substrate. The negatively charged substrates are then separated from guanosine by binding to an anion-exchange resin (AG1-X8) and centrifugation or filtration, and the product is quantitated by scintillation counting in counts per minute (cpm) of the remaining soluble material. Percent inhibition is calculated as follows: % Inhibitions 100-[(cpm compound-blank)/(cpm control- blank)X100] δ Activity is expresssed as the IC50 value, ie. the concentration required to inhibit activity of enzyme by δO per cent. Antihypertensive activity in rats 0 The ability of the compounds of the present invention to lower blood pressure can be assessed in vivo in conscious spontaneously hypertensive rats (SHR). SHR males are purchased from Taconic Farms, Germantown New York and are approximately 16-18 weeks old when anesthetized with ether. The caudal (ventral tail) artery is δ cannulated with polyethylene tubing (PEδO) and blood pressure and heart rate are recorded as described by Baum, T. et. al, J. Cardiovasc. Pharmacol. Vol δ, pp. 6δδ-667, (1983). Rats are placed into plastic cylindrical cages where they rapidly recover consciousness. Blood pressure and heart rate are allowed to stabilize for approximately 90 0 minutes prior to compound administration. Compounds are administered orally as solutions or suspensions in 0.4% aqueous methylcellulose vehicle via a feeding needle. The compound or 0.4% aqueous methylcellulose vehicle are given in a volume of 4 ml/kg to SHRs that had been fasted overnight. Activity is expressed as the fall in δ mean blood pressure (MBP) in millimeters of mercury (mm Hg). Compound-induced changes are compared with the changes in an appropriate placebo group. ACTIVITY OF POLYCYLCLIC GUANINES PDE IC SHR Antihypertensive Fall Example CaM cGMP Dose in MBP t- ϋmber (μM) (μM) (mpk) (mmHg^

Claims: IN THE CLAIMS: 1. A compound of the formula: wherein J is oxygen or sulfur, 0 R 1 is hydrogen, alkyl or alkyl substituted with aryl or hydroxy; R 2 is hydrogen, aryl, heteroaryl, cycloalkyl, alkyl or alkyl substituted with aryl, heteroaryl, hydroxy, alkoxy, amino, monoalkyl amino or dialkylamino, or -(CH2)mTCOR 20 wherein m is an integer from 1 to 6, T is oxygen or -NH- and R 20 is hydrogen, aryl, heteroaryl, alkyl or δ alkyl substituted with aryl or heteroaryl; R 3 is hydrogen, halo, trifluoromethyl, alkoxy, alkylthio, alkyl, cycloalkyl, aryl, aminosulfonyl, amino, monoalkylamino, dialkylamino, hydroxyalkylamino, aminoalkylamino, carboxy, alkoxycarbonyl or aminocarbonyl or alkyl substituted with aryl, hydroxy, alkoxy, amino, 0 monoalkylamino or dialkylamino; R a , R b , R c and R d independently represent hydrogen, alkyl, cycloalkyl or aryl; or (Ra and R b ) or (R c and R d ) or (R b and R c ) can complete a saturated ring of δ- to 7- carbon atoms, or (Ra and R b ) taken together and (R b and R c ) taken together, each complete a saturated ring δ of δ- to 7-carbon atoms, wherein each ring optionally can contain a sulfur or oxygen atom and whose carbon atoms may be optionally substituted with one or more or the following: alkenyl, alkynyl, hydroxy, carboxy, alkoxycarbonyl, alkyl or alkyl substituted with hydroxy, carboxy or alkoxycarbonyl; or such saturated ring can have two adjacent carbon atoms which are shared with an adjoining aryl ring; and n is zero or one. δ 2. A compound according to claim 1 wherein the compound is of formula (I). 3. A compound according to claim 2 wherein J is O. 0 4. A compound according to claim 2 wherein R 1 is alkyl, more preferably methyl; R 2 is hydrogen, benzyl, 4-chlorobenzyl, trimethylacetoxymethyl or cyclohexylmethyl; and R 3 is hydrogen, methyl or ethyl and n is zero. 5 5. A compound according to claim 2 wherein (R a and R b ) complete a saturated δ membered ring, (R b and R c ) complete a saturated δ, 6 or 7 membered ring or (R a and R b ) taken together and (R and R c ) taken together, each complete a saturated ring of δ- to 7-carbon atoms. 0 6. A compound according to claim 1 which is: cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3-(phenylmethyl)- cyclopenta[4,δ]imidazo[2,1-b]purin-4-one; 7,8-Dihydro-δ-methyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin-4(δH)- one; δ cis-6a,7,8,9,10,10a-Hexahydro-δ-methyl-3-(phenylmethyl)-3H- benzimidazo[2,1 -b] purin-4(δH)-one; δ,7,8,9-Tetrahydro-δ-methyl-3-(phenylmethyl)pyrimido[2,1-b]purin- 4(3H)-one; 7,8-Dihydro-8-phenyl-δ-methyl-3-(phenylmethyl)-3H-imidazo[2,1- 0 b]purin-4(δW)-one; δ',7'-Dihydro-δ'-methyl-3 , -(phenylmethyl)spiro[cyclohexane-1 ,8'-(8H)- imidazo[2,1 -b]purin]-4'(3'H)-one; cis-δ,6a, 11 ,11 a-Tetrahydro-δ-methyl-3- (phenylmethyl)indeno[1',2':4,δ]imidazo[2,1-b]purin-4(3H)-one; δ',7'-Dihydro-2',δ' dimethyl-3'-(phenylmethyl)spiro{cyclohexane- 1 δ'JD-imidazo^.l -b]purin}-4'(3'Jl)-one; 7,8-Dihydro-2,5,7,7,8(R,S)-pentamethyl-3M-imidazo[2,1-b]purin-4(5M)- one; cis-δ,6a,7,11 b-Tetrahydro-δ-methyl-3- (phenylmethyl)indeno[2',1 \:4,δ]imidazo[2,1 -b]purin-4(3N)-one; cis-δ,6a,7,8,9,9a-Hexahydro-2,δ-dimethyl-3-(phenylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4-(3H)-one; 5 , -Methyl-3'-(phenylmethyl)-spiro[cyclopentane-1 ,7 , (8Η -(3Η )- 0 imidazo[2,1 -b]purin]-4'(5'H )-one; 7,8-Dihydro-2,δ,7,7-tetramethyl-3-(phenylmethyl)-3H-imidazo[2,1- b]purin-4(δ'H)-one; 7,8-Dihydro-7(R)-phenyl-2,δ-dimethyl-3-(phenylmethyl)-3Jl-imidazo[2,1- b]purin-4(δH)-one; δ 7,8-Dihydro-2,5-dimethyl-3,7(R)-bis(phenylmethyl)-3H-imidazo[2,1 - b]purin-4(5H)-one; (±)-7,8-Dihydro-2 f δ-dimethyl-7-ethyl-3-(phenylmethyl)-3H-imidazo[2,1- b]purin-4(δJti)-one; 6a(S)-7,8,9,10,10a(R)-Hexhydro-2,δ-dimethyl-3-(phenylmethyl)-3H- 0 benzimidazo[2,1 -b]purin-4(δH)-one; 6a(R)-7,8,9,10,10a(S)-hexahydro-2,δ-dimethyl-3-(phenylmethyl)-3M- benzimidazo[2,1-b]purin-4(δM)-one; 7,8-Dihydro-2,δ-dimethyl-7(R)-isopropyl-3-(phenylmethyl)-3M- imidazo[2,1-b]purin-4(δH)-one; δ 7,8-Dihydro-2,δ,7(R)-trimethyl-3-(phenylmethyl)-3H-imidazo[2,1-b]purin- 4(δH)-one; cis-7,7a,8,9,10,10a-Hexahydro-2,δ-dimethyl-3-(phenylmethyl)-3H- cyclopenta[δ,6]pyrimido[2,1-b]purin-4(δH)-one; 7,8-Dihydro-2,δ-dimethyl-7(S)-(1-methylpropyl)-3-(phenylmethyl)-3H.- 0 imidazo[2,1-b]purin-4(δH)-one; 7,8-Dihydro-2,δ-dimethyl-7(R)-(2-methylpropyl)-3-(phenylmethyl)-3H- imidazo[2,1-b]purin-4(δfcL)-one; 7,8-Dihydro-2,δ-dimethyl-7(R,S)-(methoxycarbonyl)-3-(phenylmethyl)- 3M-imidazo[2,1-b]purin-4(δJl)-one; 7,8-Dihydro-2,δ-dimethyl-7(R,S)-(1-propyl)-3-(phenylmethyl)-3M- imidazo[2,1-b]purin-4(δJl)-one; 7,8-Dihydro-2,δ-dimethyl-7(S)-(1-methylethyl)-3-(phenylmethyl)-3ll- imidazo[2,1 -b]purin-4(δM)-one; δ 7,8-Dihydro-2,δ,7,7,8(R,S)-pentamethyl-3J -imidazo[2,1-b]purin-4(δJd)- one; δ,7,8,9-Tetrahydro-2,δ,7,9(R,S)-pentamethyl-3-(phenylmethyl)- pyrimido[2,1-b]purin-4(3ii)-one; δ,6a(H),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3- 0 (phenylmethyl)cyclopent[4,δ]imidazo[2,1 -b]purin-4(3H)-one; δ,6a(S),7,8,9,9a( : ?)-Hexahydro-2,δ-dimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; cis-6a,7,8,9,10,10a-Hexahydro-2,δ-dimethyl-3-(phenylmethyl)-3H - benzimidazo[2,1-b]purin-4(5H)-one; 5 δ , ,7'-Dihydro-2',δ'-dimethyl-3'-(phenylmethyl)spiro[cyclohexane-1 ,8'- (8H)-imidazo[2,1-b]purin]-4'(3 * H)-one; cis-δ,6a,7,8,9,9a-Hexahydro-2,δ-dimethyl-3-(phenylmethyl)- cyclohept[6,7]imidazo[2,1-b]purin-4(3H)-one; cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-2-ethyl-3-(phenylmethyl)- 0 cyclopent[4,δ]imidazo[2,1 -b]purin-4(3W)-one; cis-6a,7,8,9,10,10a-Hexahydro-δ-methyl-2-ethyl-3-(phenylmethyl)-3H- benzimidazo[2,1-b]purin-4-(δH)-one; cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-2-ethyl-3-(phenylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; δ cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-2-phenyl-3-(phenylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; cis-6a,7,8,9,10,10a-Hexahydro-δ-methyl-2-phenyl-3-(phenylmethyl)-3H- benzimidazo[2,1-b]purin-4(δ/-/)-one; cis-δ,6a,7,8,9,9a-Hexahydro-δ-methylcyclopenta[4,δ]imidazo[2,1- 0 b]purin-4(3H)-one; cis-δ,6a,7,8,9,9a-Hexahydro-2,δ-dimethylcyclopenta[4,δ]imidazo[2,1-b]- purin-4(3H)-one; cis-δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-di-methyl- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; 2'-Methyl-3'-spiro{cyclopentane-1 ,7'(8 , ii)-(3'ldJ-imidazo[2,1-b]purin}- 4'(5'H)-one; 7,8-Dihydro-2,δ-dimethyl-7(R)-(1-methylethyl)-3Jl-imidazo[2,1-b]purin- 4(δM)-one; 7,8-Dihydro-2,δ,7,7-tetramethyl-3M-imidazo[2,1-b]purin-4(δJl)-one; 7,8-Dihydro-2,δ-dimethyl-7(S)-(1-methylethyl)-3Jl-imidazo[2,1-b]purin- 4(δJd)-one; 6a(R),7,8,9,10,10a(S)-Hexahydro-2,δ-dimethyl-3M-benzimidazo[2,1 - b]purin-4(δJd)-one; 0 δ' '-Dihydro^'.δ'-dimethylspiro cyclohexane-l ,7'(8Η)-imidazo[2,1 - bjpurinH'β'JD-one; cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3- (phenylmethyl)cyclopenta[4,δ]imidazo[2,1-b]purin-4(3H)-thione; δ,6a(H),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3- δ (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-thione; cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3-(4-chlorophenyl- methyl)cyclopenta[4,δ]imidazo[2,1-b]purin-4(3H)-one; cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3-(cyclohexylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; 0 cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-3-(2-naphthylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; bromophenylmethyl)cyclopent[4,δjimidazo[2,1-b]purin-4(3Jl)-one; δ,6a(R)-7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3-(4- methoxyphenylmethyl)-cyclopent[4,δ]imidazo[2,1-b]purin-4(3Jl)- δ one; cis-δ,6a,7,8,9,9a-Hexahydro-2,3,δ-trimethylcyclopent[4,δ]imidazo[2,1- b]purin-4(3 )-one; cis-δ,6a,7,8,9,9a-Hexahydro-2-(hydroxymethyl)-δ-methyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)one; 0 cis-δ,6a,7,8,9,9a-Hexahydro-2-methylthio-δ-methyl-3-(phenylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; cis-3,4,δ,6a,7,8,9,9a-Octahydro-δ-methyl-4-oxo-3-(phenylmethyl)- cyclopent[4,δ]imidazo[2,1 -b]purin-2-carboxylic acid; cis-3,4,δ,6a,7,8,9,9a-Octahydro-δ-methyl-4-oxo-3-(phenylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-2-carboxylic acid, methyl ester; cis-δ,6a,7,8,9,9a-Hexahydro-2-bromo-δ-methyl-3-(phenylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)one; cis-δ,6a,7,8,9,9a-Hexahydro-2-(methylaminosulfonyl)-δ-methyl-3- δ (phenylmethyl)cyclopent[4,δ]imidazo[2,1 -b]purin-4(3H)one; cis-1-Cyclopentyl-δ,6a,7,8,9,9a-hexahydro-δ-methyl- cyclopent[4,δ]imidazo[2,1 -b]purin-4-(1 H)one; cis-δ,6a,7,8,9,9a-Hexahydro-3,δ-bis-(phenylmethyl) cyclopent(4,δ)imidazo(2,1-b)purin-4(3H)one; 0 cis-6a,7,8,9,10,10a-Hexahydro-3,δ-bis-(phenylmethyl)-3H- benzimidazo[2,1-b]purin-4(δH)one; cis-3-Cyclopentyl-δ,6a,7,8,9,9a-hexahydro-δ-methyl- cyclopent[4,δ]imidazo(2,1-b)purin-4(3H)one; δ'-Methyl-3'-(phenylmethyl)spiro[cyclopentane-1 ,7 , (8'H)-(3'H)- δ imidazo[2,1 -b]purin]-4'(6'H)one; 2',5'-Dimethyl-3'-(phenylmethyl)-spiro[cyclopentane-1 ,7 , (8'H)-(3'H)- imidazo[2,1-b]purin]-4'(δ'H)one; cis-δ,6a,(R)7,8,9,9a(S)-Hexahydro-δ-methyl-3- (phenylmethyl)cyclopent[4,δ]imidazo(2,1-b)purin-4(3H)one; 0 cis-3-Cyclopentyl-δ,6a,7,8,9,9a-Hexahydro-2,δ- dimethylcyclopent[4,δ]imidazo[2,1-b]purin-4(3H)one;36 5 , -Methyl-2'-trifluoromethyl-3'-(phenylmethyl)spiro{cyclo-pentane- 1 ,7'(8'^-(3'^imidazo[2,1 -b]purin}-4'(5'H)-one; 7,8-Dihydro-5,7,7-trimethyl-2-trifluoromethyl-3-(phenylmethyl)-3H- δ imidazo[2,1-b]purin-4(5Ji)-one; (+/-)-cis-δ,6a,7,8,9,9a-Hexahydro-δ-methyl-2-trifluoromethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; (+/-)-6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,δ-dimethyl-3-( phenylmethyl)- 3H-pentaleno[ 6a',1':4,δ] imidazo[2,1-b] purin-4(6H)-one; 0 (+)-6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,δ-dimethyl-3-phenylmethyl-3H- pentaleno[ 6a',1 * :4,δ] imidazo[2,1-b] purin-4(δH)-one; (-)-6a,7,8,9,9a,10,11 ,11a-Octahydro-2,δ-dimethyl-3-phenylmethyl-3H- pentaleno[6a',1':4,δ] lmidazo[2,1-b] purin-4(δH)-one; (+/-) 6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,5-dimethyl-3H-pentaleno[ 6a',1':4,5] imidazo[2,1-b] purin-4(δH)-one;. (+)-6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,5-dimethyl-3H-pentaleno[ 6a',1':4,δ] imidazo[2,1-b] purin-4(δH)-one; δ (-)-6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,δ-dimethyl-3H- pentaleno[6a',1':4,δ] imidazo[2,1-b] purin-4(δH)-one; 6a,7,8,9,10,10a,11 ,12,13,13a-Decahydro-2,δ-dimethyl-(3- phenylmethyl)napth[1 ,8a-d]imidazo[2,1 -b]purin-4(δH)one; 7(R)-Cyclohexyl-7,8-dihydro-2,δ-dimethyl-3-(phenylmethyl)-3H- 0 imidazo[2,1 -b]purin-4(3H)-one; 7(R)-Cyclohexyl-7,8-dihydro-2,δ-dimethyl-3H-imidazo[2,1-b]purin-4(δH)- one; 7(S)-Cyclohexyl-7,8-dihydro-2,δ-dimethyl-3-(phenylmethyl)-3H- imidazo[2,1 -b]purin-4(3H)-one; δ 7(S)-Cyclohexyl-7,8-dihydro-2,δ-dimethyl-3H-imidazo[2,1 -bjpurin- 4(δH)-one; δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3-[ (trimethylacetoxy)methyl]-cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)- one; 0 δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3-(4-pyridylmethyl)- cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3-[2-(1- morpholinyl)ethyl]cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; δ,6a(R),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3- δ [acetoxymethyl]cyclopent[4,δ]imidazo[2,1 -b]purin-4(3H)-one; δ,6a,7,8,9,9a-Hexahydro-2,δ,6a-trimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; δ,6a(f?),7(S),8,9,9a-Hexahydro-2,δ,6a-trimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one; 0 δ,6a(S),7(fi),8,9,9a-Hexahydro-2,δ,6a-trimethyl-3- (phenylmethyl)cyclopent[4,δ]imidazo[2,1-b]purin-4(3H)-one]; c/s-6a,7,8,9,10,10a-Hexahydro-2,δ,7-trimethyl-3-(phenylmethyl)-3H- benzimidazo[2,1-b]purin-4(δH)-one]; iδ c/s-δ,6a,7,8,9,9a-Hexahydro-2,δ,6a-trimethylcyclopent[4^jimidazo[2,1- b]purin-4(3H)-one]; or c/s-6a,7,8,9,10,10a-Hexahydro-2,δ,7-trimethyl-3H-benzimidazo[2,1- b]purin-4(δH)-one]. δ 7. A compound according to claim 1 characterized in that J is O; R 1 is alkyl, preferably methyl; 0 R 2 is hydrogen, benzyl, 4-chlorobenzyl, cyclohexylmethyl or trimethylacetoxy methyl ; R 3 is hydrogen, or alkyl such as methyl or ethyl; n is zero; and (R a and R b ) forms a saturated δ membered ring, or (R b and R c ) forms a δ saturated δ, 6 or 7 membered ring, or (R a and R b ) and (R b and R c ) each complete a saturated ring and each ring contains δ or 6 carbon atoms . 8. A compound according to claim 1 which is: δ,6a(fl),7,8,9,9a(S)-Hexahydro-2,δ-dimethyl-3- 0 (phenylmethyl)cyclopent[4,5]imidazo[2,1-b]purin-4(3H)-one; 5,6a(fl),7,8,9,9a(S)-Hexahydro-2,δ-dimethylcyclopent[4,δ]imidazo[2,1- b]purin-4(3H)-one; 2', δ'-Dimethyl-3 , -(phenylmethyl)-spiro[cyclopentane-1 ,7'(8Η)-(3'H)- imidazo[2,1 -b]purin]-4'(δ * H)one; or δ (+)-6a,7,8,9,9a,10,11 ,11 a-Octahydro-2,δ-dimethyl-3H-pentaleno [6a',1':4,δ] imidazo[2,1-b] purin-4(δH)-one. 9. A pharmaceutical composition comprising a compound of formula (I) or (!') in an amount effective to inhibit phosphodiesterase. 0 10. A pharmaceutical composition comprising a compound of formula (I) and (I * ) in an amount effective to relax smooth muscle. 11. A pharmaceutical composition comprising an anti-hypertensive or a bronchodilating effective amount of the compounds (I) and (I'). 12. A method for treating hypertension or bronchoconstriction in a δ mammal comprising administering to a mammal in need of such treatment an amount of at least one of compounds (I) and (P) effective to treat any of the above diseases. 13. A method for maintaining guanosine 3':δ'-cyclic monophosphate 0 (cGMP) levels in a mammal by administering an amount of compounds (I) and (P) effective to maintain or increase cGMP.

Inventors: LINDO NEIL A, MCKITTRICK BRIAN A, NEUSTADT BERNARD R, LINDO, NEIL, A., MCKITTRICK, BRIAN, A., NEUSTADT, BERNARD, R.
Applicants: SCHERING CORP, SCHERING CORPORATION
Application year: 1991
Main classification: C07D487
IPC codes: A61K31, A61P9, A61P11, A61P25, A61P43, C07D473, C07D487, C12N9